{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:38:17Z","timestamp":1794919097609,"version":"4.9.1"},"reference-count":837,"publisher":"Oxford University Press (OUP)","issue":"41","license":[{"start":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T00:00:00Z","timestamp":1661472000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.1093\/eurheartj\/ehac244","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T02:42:47Z","timestamp":1661481767000},"page":"4229-4361","source":"Crossref","is-referenced-by-count":3142,"title":["2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)"],"prefix":"10.1093","volume":"43","author":[{"given":"Alexander R","family":"Lyon","sequence":"first","affiliation":[{"name":"(Chairperson) ( )","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"(Chairperson) ( )","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam S","family":"Couch","sequence":"additional","affiliation":[{"name":"(Task Force Coordinator) ( )","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne C","family":"Aznar","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[{"name":"(Austria)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Boriani","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cardinale","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Cordoba","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cosyns","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Cutter","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A","family":"de Boer","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan F","family":"Dent","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"(Cyprus)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie A","family":"Gevaert","sequence":"additional","affiliation":[{"name":"(Belgium)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana A","family":"Gorog","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javid","family":"Moslehi","sequence":"additional","affiliation":[{"name":"(United States of America)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"(Portugal)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja S","family":"Salinger","sequence":"additional","affiliation":[{"name":"(Serbia)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Stephens","sequence":"additional","affiliation":[{"name":"(United Kingdom)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas M","family":"Suter","sequence":"additional","affiliation":[{"name":"(Switzerland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[{"name":"(Poland)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Tamargo","sequence":"additional","affiliation":[{"name":"(Spain)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paaladinesh","family":"Thavendiranathan","sequence":"additional","affiliation":[{"name":"(Canada)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo G","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"(Italy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van der Meer","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena J H","family":"van der Pal","sequence":"additional","affiliation":[{"name":"(Netherlands)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ESC Scientific Document Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizio","family":"Lancellotti","sequence":"additional","affiliation":[{"name":"CPG Review Coordinator Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Thuny","sequence":"additional","affiliation":[{"name":"CPG Review Coordinator France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[{"name":"Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berthe","family":"Aleman","sequence":"additional","affiliation":[{"name":"Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Alexandre","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Barac","sequence":"additional","affiliation":[{"name":"United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Borger","sequence":"additional","affiliation":[{"name":"Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Casado-Arroyo","sequence":"additional","affiliation":[{"name":"Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cautela","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"\u010celutkien\u0117","sequence":"additional","affiliation":[{"name":"Lithuania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cikes","sequence":"additional","affiliation":[{"name":"Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Cohen-Solal","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreena","family":"Dhiman","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Edvardsen","sequence":"additional","affiliation":[{"name":"Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[{"name":"United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Grapsa","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[{"name":"Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiny","family":"Jaarsma","sequence":"additional","affiliation":[{"name":"Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kahan","sequence":"additional","affiliation":[{"name":"Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konradi","sequence":"additional","affiliation":[{"name":"Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C","family":"Koskinas","sequence":"additional","affiliation":[{"name":"Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ky","sequence":"additional","affiliation":[{"name":"United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[{"name":"Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[{"name":"Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[{"name":"Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja-Lisa","family":"L\u00f8chen","sequence":"additional","affiliation":[{"name":"Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Malaczynska-Rajpold","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mindham","sequence":"additional","affiliation":[{"name":"United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Moonen","sequence":"additional","affiliation":[{"name":"Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas G","family":"Neilan","sequence":"additional","affiliation":[{"name":"United States of America"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Cosedis","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Sonia","family":"Petronio","sequence":"additional","affiliation":[{"name":"Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[{"name":"Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[{"name":"Kazakhstan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe-Elie","family":"Salem","sequence":"additional","affiliation":[{"name":"France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sitges","sequence":"additional","affiliation":[{"name":"Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien ten","family":"Berg","sequence":"additional","affiliation":[{"name":"Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[{"name":"Canada\/United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Tycinska","sequence":"additional","affiliation":[{"name":"Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Zamorano","sequence":"additional","affiliation":[{"name":"Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Laredj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parounak","family":"Zelveian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P","family":"Rainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuad","family":"Samadov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uladzimir","family":"Andrushchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard L","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirsad","family":"Selimovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jure","family":"Samardzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evagoras","family":"Economides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Pudil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten M","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A","family":"Kafafy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riina","family":"Vettus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvi","family":"Tuohinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ederhy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zurab","family":"Pagava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienush","family":"Rassaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Briasoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1niel","family":"Czuriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl K","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaza","family":"Iakobishvili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Parrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edita Pllana","family":"Pruthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkin","family":"Mirrakhimov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskars","family":"Kalejs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Benlamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"\u017daliaduonyt\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice M","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bursacovschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatif","family":"Benyass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijan","family":"Bosevski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Przemys\u0142aw","family":"Leszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Fiuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra","family":"Jurcut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Vasyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Foscoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Simic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Slanina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luka","family":"Lipar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martin-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"H\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto","family":"Kurmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Abid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cafer","family":"Zorkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nesukay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Manisty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigora","family":"Srojidinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Baigent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Aboyans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotiris","family":"Antoniou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arbelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Asteggiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Baumbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Borger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"\u010celutkien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Cikes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Halvorsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Iung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiny","family":"Jaarsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Konradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos C","family":"Koskinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Kotecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ales","family":"Linhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja-Lisa","family":"L\u00f8chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mindham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Cosedis","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen E","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Rakisheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Sitges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhian M","family":"Touyz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,26]]},"reference":[{"key":"2026080909465417100_ehac244-B1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: Cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"2026080909465417100_ehac244-B3","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2026080909465417100_ehac244-B4","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B5","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B6","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s11764-019-00795-5","article-title":"Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group","volume":"13","author":"Michel","year":"2019","journal-title":"J Cancer Surviv"},{"key":"2026080909465417100_ehac244-B7","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/S1470-2045(14)70409-7","article-title":"Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"16","author":"Armenian","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000514693","article-title":"The concept of cancer survivorship and models for long-term follow-up","volume":"54","author":"van Kalsbeek","year":"2021","journal-title":"Front Horm Res"},{"key":"2026080909465417100_ehac244-B9","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","article-title":"Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026080909465417100_ehac244-B10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41569-020-0347-2","article-title":"Vascular toxic effects of cancer therapies","volume":"17","author":"Herrmann","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026080909465417100_ehac244-B11","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B12","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-021-06192-w","article-title":"Incidence of cardiotoxicity and validation of the Heart Failure Association\u2013International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer","volume":"188","author":"Battisti","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B14","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B15","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jacc.2011.08.026","article-title":"Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T","volume":"58","author":"Jaffe","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2018.01.070","article-title":"Elevated cardiac troponin T in patients with skeletal myopathies","volume":"71","author":"Schmid","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B17","doi-asserted-by":"crossref","first-page":"100216","DOI":"10.1016\/j.esmoop.2021.100216","article-title":"Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy","volume":"6","author":"Delombaerde","year":"2021","journal-title":"ESMO Open"},{"key":"2026080909465417100_ehac244-B18","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","article-title":"Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations","volume":"72","author":"Ferreira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B19","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B20","doi-asserted-by":"crossref","first-page":"e003264","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B21","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/1474515119856207","article-title":"Risk prediction tools in cardiovascular disease prevention: a report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"18","author":"Rossello","year":"2019","journal-title":"Eur J Cardiovasc Nurs"},{"key":"2026080909465417100_ehac244-B24","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B25","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3747\/co.24.3349","article-title":"Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population","volume":"24","author":"Rushton","year":"2017","journal-title":"Curr Oncol"},{"key":"2026080909465417100_ehac244-B27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-007-9803-5","article-title":"The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines","volume":"107","author":"Dranitsaris","year":"2008","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B28","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1093\/eurheartj\/ehz460","article-title":"Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study","volume":"40","author":"Abdel-Qadir","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaccao.2019.10.008","article-title":"Symptomatic heart failure in acute leukemia patients treated with anthracyclines","volume":"1","author":"Kang","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.recesp.2020.11.014","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mart\u00edn Garc\u00eda","year":"2021","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"issue":"(6)","key":"2026080909465417100_ehac244-B31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: insights from the CARDIOTOX registry","volume":"29","author":"Caro-Cod\u00f3n","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B32","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","article-title":"Derivation of anthracycline and anthraquinone equivalence ratios to doxorubicin for late-onset cardiotoxicity","volume":"5","author":"Feijen","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B33","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ejhf.1292","article-title":"Activity and outcomes of a cardio-oncology service in the United Kingdom\u2014a five-year experience","volume":"20","author":"Pareek","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B34","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","article-title":"Shared risk factors in cardiovascular disease and cancer","volume":"133","author":"Koene","year":"2016","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B35","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2606","article-title":"Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart","volume":"37","author":"Caocci","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026080909465417100_ehac244-B36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jacc.2019.06.007","article-title":"Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC review topic of the week","volume":"74","author":"Libby","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B38","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaccao.2020.09.006","article-title":"Genetics of anthracycline cardiomyopathy in cancer survivors","volume":"2","author":"Bhatia","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/PPO.0000000000000101","article-title":"Lifestyle and cancer risk","volume":"21","author":"Katzke","year":"2015","journal-title":"Cancer J"},{"key":"2026080909465417100_ehac244-B40","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.3390\/ijerph17072326","article-title":"Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds","volume":"17","author":"Sharifi-Rad","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"2026080909465417100_ehac244-B41","first-page":"460","article-title":"Outdoor air pollution and cancer: an overview of the current evidence and public health recommendations","volume":"70","author":"Turner","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"2026080909465417100_ehac244-B42","doi-asserted-by":"crossref","first-page":"334","DOI":"10.12997\/jla.2020.9.3.334","article-title":"Are persistent organic pollutants linked to lipid abnormalities, atherosclerosis and cardiovascular disease? A review","volume":"9","author":"Lind","year":"2020","journal-title":"J Lipid Atheroscler"},{"key":"2026080909465417100_ehac244-B43","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/ejhf.1985","article-title":"The cancer patient and cardiology","volume":"22","author":"Zamorano","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B44","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ccep.2015.03.013","article-title":"QT prolongation and oncology drug development","volume":"7","author":"Fradley","year":"2015","journal-title":"Card Electrophysiol Clin"},{"key":"2026080909465417100_ehac244-B45","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ejca.2007.10.001","article-title":"Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development","volume":"44","author":"Curigliano","year":"2008","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11886-016-0730-0","article-title":"Arrhythmias and other electrophysiology issues in cancer patients receiving chemotherapy or radiation","volume":"18","author":"Viganego","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2026080909465417100_ehac244-B48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3332\/ecancer.2008.130","article-title":"QTc prolongation assessment in anticancer drug development: clinical and methodological issues","volume":"3","author":"Curigliano","year":"2009","journal-title":"Ecancermedicalscience"},{"key":"2026080909465417100_ehac244-B49","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B50","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026080909465417100_ehac244-B51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15384047.2017.1394554","article-title":"Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia","volume":"19","author":"Mato","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"2026080909465417100_ehac244-B52","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.bbmt.2013.05.019","article-title":"Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation","volume":"19","author":"Singla","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080909465417100_ehac244-B53","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B54","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B55","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B56","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1200\/JCO.2010.30.3404","article-title":"Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes","volume":"30","author":"Lipshultz","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B57","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJMoa035153","article-title":"The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia","volume":"351","author":"Lipshultz","year":"2004","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B58","doi-asserted-by":"crossref","first-page":"32519","DOI":"10.18632\/oncotarget.8685","article-title":"Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: results from a randomized prospective clinical trial","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget"},{"key":"2026080909465417100_ehac244-B59","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B60","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","article-title":"Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab","volume":"61","author":"Putt","year":"2015","journal-title":"Clin Chem"},{"key":"2026080909465417100_ehac244-B61","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B62","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B63","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ejhf.1494","article-title":"Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations","volume":"21","author":"Mueller","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B64","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijcard.2009.09.564","article-title":"Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide","volume":"148","author":"Feola","year":"2011","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B65","doi-asserted-by":"crossref","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","article-title":"Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction","volume":"9","author":"Demissei","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B66","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B67","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B68","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: the CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B69","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B70","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9051418","article-title":"Circulating microRNAs as potential predictors of anthracycline-induced troponin elevation in breast cancer patients: diverging effects of doxorubicin and epirubicin","volume":"9","author":"Gioffr\u00e9","year":"2020","journal-title":"J Clin Med"},{"key":"2026080909465417100_ehac244-B71","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/CIRCRESAHA.116.309004","article-title":"Baseline immunoglobulin e levels as a marker of doxorubicin- and trastuzumab-associated cardiac dysfunction","volume":"119","author":"Beer","year":"2016","journal-title":"Circ Res"},{"key":"2026080909465417100_ehac244-B72","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jcmg.2018.06.003","article-title":"Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient","volume":"11","author":"Plana","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B73","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","article-title":"Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"18","author":"Galderisi","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B74","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.2013.53.9288","article-title":"Trastuzumab-associated cardiac events at 8 years of median follow-up in the herceptin adjuvant trial (BIG 1-01)","volume":"32","author":"De Azambuja","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B75","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/ehjci\/jex033","article-title":"2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: A balance with feasibility","volume":"18","author":"Santoro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B76","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jcmg.2018.01.015","article-title":"Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction","volume":"11","author":"Zhang","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B78","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B79","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.jacc.2012.01.037","article-title":"Performance of 3-dimensional echocardiography in measuring left ventricular volumes and ejection fraction: a systematic review and meta-analysis","volume":"59","author":"Dorosz","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B80","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.echo.2013.12.005","article-title":"Analysis of left ventricular volumes and function: a multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography","volume":"27","author":"Hoffmann","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B81","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/eurheartj\/ehn484","article-title":"Left ventricular volume measurement with echocardiography: a comparison of left ventricular opacification, three-dimensional echocardiography, or both with magnetic resonance imaging","volume":"30","author":"Jenkins","year":"2009","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.echo.2017.11.013","article-title":"Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography Guidelines Update","volume":"31","author":"Porter","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B83","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","article-title":"Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography","volume":"14","author":"Houbois","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B84","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1002\/ejhf.1847","article-title":"Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer","volume":"22","author":"Dobbin","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B85","first-page":"977","article-title":"Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50\u201359% treated with anthracyclines","volume":"16","author":"Mousavi","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B86","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.1330","article-title":"Innovative imaging methods in heart failure: a shifting paradigm in cardiac assessment. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"\u010celutkien\u0117","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B87","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1136\/heartjnl-2014-305538","article-title":"Prognostic implications of global LV dysfunction: a systematic review and meta-analysis of global longitudinal strain and ejection fraction","volume":"100","author":"Kalam","year":"2014","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B88","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00392-018-1363-7","article-title":"Test\u2013retest reliability of new and conventional echocardiographic parameters of left ventricular systolic function","volume":"108","author":"Baron","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026080909465417100_ehac244-B89","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/heartjnl-2019-316297","article-title":"Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity","volume":"106","author":"Lambert","year":"2020","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B90","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jcmg.2018.03.003","article-title":"Single versus standard multiview assessment of global longitudinal strain for the diagnosis of cardiotoxicity during cancer therapy","volume":"11","author":"Thavendiranathan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B91","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ehjci\/jet159","article-title":"Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection","volume":"15","author":"Negishi","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B92","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B93","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026080909465417100_ehac244-B94","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"15","author":"Plana","year":"2014","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B95","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.echo.2015.06.011","article-title":"Head-to-head comparison of global longitudinal strain measurements among nine different vendors: the EACVI\/ASE inter-vendor comparison study","volume":"28","author":"Farsalinos","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B96","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.jcmg.2015.11.024","article-title":"Noninvasive measures of ventricular\u2013arterial coupling and circumferential strain predict cancer therapeutics\u2013related cardiac dysfunction","volume":"9","author":"Narayan","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B97","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/CRD.0000000000000161","article-title":"Ability of nonstrain diastolic parameters to predict doxorubicin-induced cardiomyopathy: a systematic review with meta-analysis","volume":"26","author":"Nagiub","year":"2018","journal-title":"Cardiol Rev"},{"key":"2026080909465417100_ehac244-B98","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jcmg.2019.07.018","article-title":"Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy","volume":"13","author":"Upshaw","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B99","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2019.01.056","article-title":"Comparison of Framingham risk score and chest-CT identified coronary artery calcification in breast cancer patients to predict cardiovascular events","volume":"289","author":"Phillips","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B100","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B101","first-page":"635","article-title":"Cardiac computed tomography in cardio-oncology: JACC: CardioOncology primer","volume":"3","author":"Lopez-Mattei","year":"2021","journal-title":"Cardio Oncol"},{"key":"2026080909465417100_ehac244-B102","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B103","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/jamacardio.2021.5881","article-title":"A combined echocardiography approach for the diagnosis of cancer therapy-related cardiac dysfunction in women with early-stage breast cancer","volume":"7","author":"Esmaeilzadeh","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026080909465417100_ehac244-B104","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B105","doi-asserted-by":"crossref","first-page":"e012459","DOI":"10.1161\/CIRCIMAGING.121.012459","article-title":"Multiparametric early detection and prediction of cardiotoxicity using myocardial strain, T1 and T2 mapping, and biochemical markers: a longitudinal cardiac resonance imaging study during 2 years of follow-up","volume":"14","author":"Giusca","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B106","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1007\/s10554-019-01648-z","article-title":"Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study","volume":"35","author":"Dhir","year":"2019","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B107","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12968-017-0348-4","article-title":"Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance","volume":"19","author":"Huang","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026080909465417100_ehac244-B109","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1242\/jeb.201.8.1051","article-title":"Limits for oxygen and substrate transport in mammals","volume":"201","author":"Hoppeler","year":"1998","journal-title":"J Exp Biol"},{"key":"2026080909465417100_ehac244-B110","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.mayocp.2016.10.003","article-title":"Reference standards for cardiorespiratory fitness measured with cardiopulmonary exercise testing using cycle ergometry: data from the Fitness Registry and the Importance of Exercise National Database (FRIEND) registry","volume":"92","author":"Kaminsky","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2026080909465417100_ehac244-B111","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.jacc.2018.08.2166","article-title":"Cardiorespiratory fitness and mortality in healthy men and women","volume":"72","author":"Imboden","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B112","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/clc.4960130809","article-title":"Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity","volume":"13","author":"Jett\u00e9","year":"1990","journal-title":"Clin Cardiol"},{"key":"2026080909465417100_ehac244-B113","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1161\/CIR.0000000000000461","article-title":"Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association","volume":"134","author":"Ross","year":"2016","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/annonc\/mdu250","article-title":"Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis","volume":"26","author":"Schmid","year":"2015","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B115","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.110.003236","article-title":"Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality","volume":"123","author":"Gupta","year":"2011","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B116","doi-asserted-by":"crossref","first-page":"e001495","DOI":"10.1161\/JAHA.114.001495","article-title":"Self-reported cardiorespiratory fitness: prediction and classification of risk of cardiovascular disease mortality and longevity\u2014a prospective investigation in the Copenhagen City Heart Study","volume":"4","author":"Holtermann","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B117","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/eurheartj\/ehs097","article-title":"A non-exercise testing method for estimating cardiorespiratory fitness: associations with all-cause and cardiovascular mortality in a pooled analysis of eight population-based cohorts","volume":"34","author":"Stamatakis","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B118","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCOUTCOMES.113.000531","article-title":"Prediction of 30-year risk for cardiovascular mortality by fitness and risk factor levels: the Cooper Center Longitudinal Study","volume":"7","author":"Wickramasinghe","year":"2014","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026080909465417100_ehac244-B119","doi-asserted-by":"crossref","DOI":"10.1177\/2047487320930873","article-title":"Cardiorespiratory fitness and survival following cancer diagnosis","author":"Fardman","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B120","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/ehjqcco\/qcaa015","article-title":"Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer","volume":"6","author":"Groarke","year":"2020","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026080909465417100_ehac244-B121","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12282-019-00975-2","article-title":"Cardiorespiratory fitness predicts cardiovascular health in breast cancer survivors, independent of body composition, age and time post-treatment completion","volume":"26","author":"Jones","year":"2019","journal-title":"Breast Cancer"},{"key":"2026080909465417100_ehac244-B122","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jtho.2016.04.021","article-title":"The utility of exercise testing in patients with lung cancer","volume":"11","author":"Ha","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026080909465417100_ehac244-B123","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/bja\/aet408","article-title":"Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: a prospective blinded observational study","volume":"112","author":"West","year":"2014","journal-title":"Br J Anaesth"},{"key":"2026080909465417100_ehac244-B124","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/bjs.9551","article-title":"Cardiopulmonary exercise testing for the prediction of morbidity risk after rectal cancer surgery","volume":"101","author":"West","year":"2014","journal-title":"Br J Surg"},{"key":"2026080909465417100_ehac244-B125","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1093\/eurheartj\/ehac270","article-title":"2022 ESC guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B126","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ng.3374","article-title":"A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer","volume":"47","author":"Aminkeng","year":"2015","journal-title":"Nat Genet"},{"key":"2026080909465417100_ehac244-B127","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014a report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B128","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B129","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B130","volume-title":"ESC CardioMed","author":"European Society of Cardiology","year":"2018","edition":"3rd ed"},{"key":"2026080909465417100_ehac244-B131","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B132","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/ejhf.1165","article-title":"Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge","volume":"20","author":"Ameri","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B133","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/2047487319874900","article-title":"The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology","volume":"28","author":"D\u2019Ascenzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B134","doi-asserted-by":"crossref","first-page":"e003954","DOI":"10.1161\/JAHA.116.003954","article-title":"Association between life\u2019s simple 7 and noncardiovascular disease: the multi-ethnic study of atherosclerosis","volume":"5","author":"Ogunmoroti","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B135","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaccao.2021.11.002","article-title":"Healthy lifestyle benefits both cancer and cardiovascular disease: more bang for the buck","volume":"3","author":"Michos","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B136","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","article-title":"The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: systematic review","volume":"29","author":"Murray","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B137","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/CIRCULATIONAHA.117.024671","article-title":"Exercise therapy and cardiovascular toxicity in cancer","volume":"137","author":"Scott","year":"2018","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B138","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B139","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B141","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B142","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/eurheartj\/ehy365","article-title":"Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications","volume":"40","author":"Ferdinandy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B143","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B144","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B145","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies)","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B146","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1016\/j.jacc.2018.02.049","article-title":"Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial","volume":"71","author":"Avila","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B147","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B148","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ejhf.196","article-title":"Protective effects of spironolactone against anthracycline-induced cardiomyopathy","volume":"17","author":"Akpek","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B149","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B150","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B151","doi-asserted-by":"crossref","first-page":"e006513","DOI":"10.1161\/JAHA.117.006513","article-title":"Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) study","volume":"6","author":"Gulati","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B152","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B153","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B154","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer a randomized clinical trial","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B155","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2021","journal-title":"Intern Emerg Med"},{"key":"2026080909465417100_ehac244-B156","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10741-018-9755-3","article-title":"Protective role of beta-blockers in chemotherapy-induced cardiotoxicity\u2014a systematic review and meta-analysis of carvedilol","volume":"24","author":"Huang","year":"2019","journal-title":"Heart Fail Rev"},{"key":"2026080909465417100_ehac244-B157","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaccao.2019.08.006","article-title":"Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy","volume":"1","author":"Vaduganathan","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B158","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaccao.2019.08.003","article-title":"Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer","volume":"1","author":"Macedo","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B159","doi-asserted-by":"crossref","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol Res"},{"key":"2026080909465417100_ehac244-B160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","article-title":"Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials","volume":"26","author":"Fang","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2026080909465417100_ehac244-B161","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B162","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B163","author":"European Medicines Agency"},{"key":"2026080909465417100_ehac244-B164","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B165","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.ejca.2015.07.031","article-title":"Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis","volume":"51","author":"Yamaguchi","year":"2015","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B166","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1200\/JCO.1997.15.4.1333","article-title":"Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy","volume":"15","author":"Swain","year":"1997","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B167","first-page":"CD003917","article-title":"Cardioprotective interventions for cancer patients receiving anthracyclines","volume":"2011","author":"van Dalen","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080909465417100_ehac244-B168","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug Saf"},{"key":"2026080909465417100_ehac244-B169","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nrc2288","article-title":"Innovations in image-guided radiotherapy","volume":"7","author":"Verellen","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2026080909465417100_ehac244-B170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat Rev Dis Prim"},{"key":"2026080909465417100_ehac244-B171","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jamaoncol.2020.7468","article-title":"Association of breast cancer irradiation with cardiac toxic effects: a narrative review","volume":"7:","author":"Meattini","year":"2021;","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B172","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jtho.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026080909465417100_ehac244-B173","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the International Cardio-Oncology Society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B174","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.clon.2016.06.007","article-title":"It\u2019s PRIMETIME. Postoperative avoidance of radiotherapy: biomarker selection of women at very low risk of local recurrence","volume":"28","author":"Kirwan","year":"2016","journal-title":"Clin Oncol"},{"key":"2026080909465417100_ehac244-B175","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"Cardinale","year":"2006","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B176","doi-asserted-by":"crossref","first-page":"e018393","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin exposure and risk of heart failure after anthracycline-or trastuzumab-based chemotherapy for early breast cancer: a propensity score\u2012matched cohort study","volume":"10","author":"Abdel-Qadir","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B177","first-page":"153","article-title":"Cardioprotective effect of statins in patients with HER2-positive breast cancer receiving trastuzumab therapy","volume":"35","author":"Calvillo-Arg\u00fcelles","year":"2019","journal-title":"Can J Cardiol"},{"key":"2026080909465417100_ehac244-B178","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.jacc.2012.07.067","article-title":"Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study","volume":"60","author":"Seicean","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B179","first-page":"302","article-title":"Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function","volume":"31","author":"Chotenimitkhun","year":"2015","journal-title":"Can J Cardiol"},{"key":"2026080909465417100_ehac244-B180","first-page":"1395","article-title":"Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and\/or trastuzumab: a systematic review and meta-analysis","volume":"32","author":"Obasi","year":"2021","journal-title":"Cancer Causes Control"},{"key":"2026080909465417100_ehac244-B181","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.3390\/jcm10163731","article-title":"Statin use can attenuate the decline in left ventricular ejection fraction and the incidence of cardiomyopathy in cardiotoxic chemotherapy recipients: a systematic review and meta-analysis","volume":"10","author":"Kim","year":"2021","journal-title":"J Clin Med"},{"key":"2026080909465417100_ehac244-B182","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2016.68.3482","article-title":"Statins are associated with reduced mortality in multiple myeloma","volume":"34","author":"Sanfilippo","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B183","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1016\/j.clml.2020.07.003","article-title":"Statins reduce mortality in multiple myeloma: a population-based US study","volume":"20","author":"Afzal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026080909465417100_ehac244-B184","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/1074248418821721","article-title":"Effect of rosuvastatin in preventing chemotherapy-induced cardiotoxicity in women with breast cancer: a randomized, single-blind, placebo-controlled trial","volume":"24","author":"Nabati","year":"2019","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"2026080909465417100_ehac244-B185","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.amjcard.2021.07.001","article-title":"Meta-analysis evaluating the use of statins to attenuate cardiotoxicity in cancer patients receiving anthracyclines and trastuzumab-based chemotherapy","volume":"156","author":"Shahid","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B186","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/FJC.0000000000000470","article-title":"Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity","volume":"69","author":"Nabati","year":"2017","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026080909465417100_ehac244-B187","doi-asserted-by":"crossref","first-page":"e10875","DOI":"10.2196\/10875","article-title":"Electronic systems for patients to report and manage side effects of cancer treatment: systematic review","volume":"21","author":"Warrington","year":"2019","journal-title":"J Med Internet Res"},{"key":"2026080909465417100_ehac244-B188","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.recesp.2016.12.021","article-title":"Cardio-onco-hematology in clinical practice. Position paper and recommendations","volume":"70","author":"L\u00f3pez-Fern\u00e1ndez","year":"2017","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"key":"2026080909465417100_ehac244-B189","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","article-title":"Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study","volume":"175","author":"Lynce","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B190","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience","volume":"20","author":"Fornaro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B191","doi-asserted-by":"crossref","first-page":"e1054","DOI":"10.1161\/CIR.0000000000000490","article-title":"Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association","volume":"135","author":"Chow","year":"2017","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B192","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/ejhf.273","article-title":"State of the art: newer biomarkers in heart failure","volume":"17","author":"De Boer","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B193","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","article-title":"Novel heart failure biomarkers: why do we fail to exploit their potential?","volume":"55","author":"Piek","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"2026080909465417100_ehac244-B194","doi-asserted-by":"crossref","first-page":"4155","DOI":"10.7150\/thno.26055","article-title":"Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production","volume":"8","author":"Du","year":"2018","journal-title":"Theranostics"},{"key":"2026080909465417100_ehac244-B195","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2020.07.044","article-title":"Sex-specific associations of cardiovascular risk factors and biomarkers with incident heart failure","volume":"76","author":"Suthahar","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B196","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11912-020-00930-x","article-title":"Cardiac biomarkers in patients with cancer: considerations, clinical implications, and future avenues","volume":"22","author":"Bracun","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"2026080909465417100_ehac244-B197","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan","year":"2020","journal-title":"J Cardiovasc Transl Res"},{"key":"2026080909465417100_ehac244-B198","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.recesp.2016.12.027","article-title":"Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies","volume":"70","author":"L\u00f3pez-Fern\u00e1ndez","year":"2017","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"key":"2026080909465417100_ehac244-B199","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/eurjhf\/hfq213","article-title":"Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology","volume":"13","author":"Eschenhagen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B200","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/echo.14800","article-title":"Focused echocardiography in cardio-oncology","volume":"37","author":"Keramida","year":"2020","journal-title":"Echocardiography"},{"key":"2026080909465417100_ehac244-B201","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jaccao.2020.10.011","article-title":"Strain imaging in cardio-oncology","volume":"2","author":"Liu","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B203","doi-asserted-by":"crossref","first-page":"ehaa946.3282","DOI":"10.1093\/ehjci\/ehaa946.3282","article-title":"Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 1 year results of the SUCCOUR trial","volume":"41","author":"Negishi","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B204","doi-asserted-by":"crossref","DOI":"10.1007\/s10554-021-02271-7","article-title":"Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients","author":"Vallabhaneni","year":"2021;37:3003\u20133017.","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B205","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1038\/s41598-019-48685-1","article-title":"Effect of comprehensive initial training on the variability of left ventricular measures using fast-SENC cardiac magnetic resonance imaging","volume":"9","author":"Lapinskas","year":"2019","journal-title":"Sci Rep"},{"key":"2026080909465417100_ehac244-B206","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jcmg.2020.10.024","article-title":"Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients","volume":"14","author":"Korosoglou","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B207","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B208","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B209","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjcard.2015.04.064","article-title":"Major cardiac events and the value of echocardiographic evaluation in patients receiving anthracycline-based chemotherapy","volume":"116","author":"Wang","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10549-019-05178-z","article-title":"Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy","volume":"176","author":"Abu-Khalaf","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","article-title":"The utility of point-of-care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study","volume":"22","author":"Lenihan","year":"2016","journal-title":"J Card Fail"},{"key":"2026080909465417100_ehac244-B212","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/ehf2.12695","article-title":"Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial","volume":"7","author":"Meessen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026080909465417100_ehac244-B213","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0004563216650464","article-title":"High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury","volume":"54","author":"Jones","year":"2017","journal-title":"Ann Clin Biochem"},{"key":"2026080909465417100_ehac244-B214","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/14737140.2018.1477596","article-title":"Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects","volume":"18","author":"Brand\u00e3o","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026080909465417100_ehac244-B215","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026080909465417100_ehac244-B216","doi-asserted-by":"crossref","first-page":"H1271","DOI":"10.1152\/ajpheart.00517.2014","article-title":"ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity","volume":"309","author":"Belmonte","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026080909465417100_ehac244-B217","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2017.1351541","article-title":"Breast cancer treatment-induced cardiotoxicity","volume":"16","author":"Martel","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"2026080909465417100_ehac244-B218","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-019-05453-z","article-title":"A pooled analysis of the cardiac events in the trastuzumab adjuvant trials","volume":"179","author":"de Azambuja","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B219","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","article-title":"Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"122","author":"Eiger","year":"2020","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B220","doi-asserted-by":"crossref","first-page":"7811","DOI":"10.1200\/JCO.2005.02.4091","article-title":"Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, HER2-overexpressing breast cancer","volume":"23","author":"Tan-Chiu","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B221","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Martin","year":"2011","journal-title":"NEJM"},{"key":"2026080909465417100_ehac244-B222","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B223","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B224","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B225","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B226","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.echo.2015.02.001","article-title":"Time trends of left ventricular ejection fraction and myocardial deformation indices in a cohort of women with breast cancer treated with anthracyclines, taxanes, and trastuzumab","volume":"28","author":"Tan","year":"2015","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B227","first-page":"510","article-title":"A prospective study about trastuzumab-induced cardiotoxicity in HER2-positive breast cancer","volume":"43","author":"Ben Kridis","year":"2020","journal-title":"Am J Clin Oncol Cancer Clin Trials"},{"key":"2026080909465417100_ehac244-B228","doi-asserted-by":"crossref","first-page":"741451","DOI":"10.3389\/fphar.2021.741451","article-title":"Cardiotoxicity of epidermal growth factor receptor 2-targeted drugs for breast cancer","volume":"12","author":"Yang","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026080909465417100_ehac244-B229","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","article-title":"2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology","volume":"34","author":"Task Force Members","year":"2013","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B230","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","article-title":"How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach","volume":"2","author":"Padegimas","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B231","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B232","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/annonc\/mdf035","article-title":"Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil","volume":"13","author":"Frickhofen","year":"2002","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B233","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/2050-6511-15-47","article-title":"A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity","volume":"15","author":"Polk","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"key":"2026080909465417100_ehac244-B234","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1093\/ehjci\/jeab244","article-title":"Non-invasive imaging in coronary syndromes: recommendations of the European Association of Cardiovascular Imaging and the American Society of Echocardiography, in collaboration with the American Society of Nuclear Cardiology, Society of Cardiovascular Comuted Tomography, and Society for Cardiovascular Magnetic Resonance","volume":"23","author":"Edvardsen","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B235","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918780140","article-title":"5-fluorouracil and cardiotoxicity: a review","volume":"10","author":"Sara","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026080909465417100_ehac244-B236","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","article-title":"Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives","volume":"23","author":"Bair","year":"2013","journal-title":"Trends Cardiovasc Med"},{"key":"2026080909465417100_ehac244-B237","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1200\/JCO.2009.27.2757","article-title":"Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"28","author":"Choueiri","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B238","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","article-title":"Cardiovascular safety of tyrosine kinase inhibitors: With a special focus on cardiac repolarisation (QT interval)","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Saf"},{"key":"2026080909465417100_ehac244-B239","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","article-title":"Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: a systematic review and meta-analysis","volume":"53","author":"Abdel-Qadir","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026080909465417100_ehac244-B240","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40959-019-0042-9","article-title":"Takotsubo cardiomyopathy in cancer patients","volume":"5","author":"Desai","year":"2019","journal-title":"Cardio-Oncology"},{"key":"2026080909465417100_ehac244-B241","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.110.992230","article-title":"Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension","volume":"124","author":"Nazer","year":"2011","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B242","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719843435","article-title":"Cardiotoxicity due to targeted anticancer agents: a growing challenge","volume":"13","author":"Shah","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"2026080909465417100_ehac244-B243","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc072330","article-title":"Home blood-pressure monitoring in patients receiving sunitinib","volume":"358","author":"Azizi","year":"2008","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B244","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cncr.28972","article-title":"Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway","volume":"121","author":"Hamnvik","year":"2015","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B245","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.critrevonc.2014.12.008","article-title":"Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"94","author":"Ghatalia","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080909465417100_ehac244-B246","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.echo.2018.09.019","article-title":"Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers","volume":"32","author":"Nhola","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B247","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMc1108849","article-title":"Reversible cardiomyopathy associated with sunitinib and sorafenib","volume":"365","author":"Uraizee","year":"2011","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B248","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"2026080909465417100_ehac244-B249","doi-asserted-by":"crossref","first-page":"e30353","DOI":"10.1371\/journal.pone.0030353","article-title":"Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis","volume":"7","author":"Zang","year":"2012","journal-title":"PLoS One"},{"key":"2026080909465417100_ehac244-B250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B251","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ehjcvp\/pvaa037","article-title":"Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database","volume":"7","author":"Alexandre","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026080909465417100_ehac244-B252"},{"key":"2026080909465417100_ehac244-B253"},{"key":"2026080909465417100_ehac244-B254","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.ahj.2011.10.018","article-title":"Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"163","author":"Steingart","year":"2012","journal-title":"Am Heart J"},{"key":"2026080909465417100_ehac244-B255","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026080909465417100_ehac244-B256","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","author":"Barber","year":"2017","journal-title":"Hematology"},{"key":"2026080909465417100_ehac244-B257","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B258","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B259","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer treatment-induced arrhythmias: focus on chemotherapy and targeted therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"2026080909465417100_ehac244-B260","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.115.018347","article-title":"Vascular toxicities of cancer therapies: the old and the new\u2014an evolving avenue","volume":"133","author":"Herrmann","year":"2016","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B261","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3390\/cancers12040826","article-title":"Cardiovascular toxicity of tyrosine kinase inhibitors used in chronic myeloid leukemia: an analysis of the FDA adverse event reporting system database (FAERS)","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026080909465417100_ehac244-B262","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.15080","article-title":"Optimising outcomes for patients with chronic lymphocytic leukaemia on ibrutinib therapy: European recommendations for clinical practice","volume":"180","author":"Gribben","year":"2018","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B263","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1080\/10428194.2016.1257795","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)","volume":"58","author":"Shanafelt","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"2026080909465417100_ehac244-B264","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B265","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"2026080909465417100_ehac244-B266","first-page":"1203","article-title":"Ibrutinib-associated atrial fibrillation: a practical approach","volume":"5","author":"L\u00f3pez-Fern\u00e1ndez","year":"2018","journal-title":"Ann Hematol Oncol"},{"key":"2026080909465417100_ehac244-B267","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B268","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B269","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B270","year":"2022","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE) v6.0"},{"key":"2026080909465417100_ehac244-B271","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"2026080909465417100_ehac244-B272","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/europace\/euac038","article-title":"How to use digital devices to detect and manage arrhythmias: an EHRA practical guide","volume":"24","author":"Svennberg","year":"2022","journal-title":"Europace"},{"key":"2026080909465417100_ehac244-B273","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B274","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B275","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3109\/10428194.2016.1169408","article-title":"Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma","volume":"57","author":"Lee","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2026080909465417100_ehac244-B276","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"2026080909465417100_ehac244-B277","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"2026080909465417100_ehac244-B278","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1056\/NEJMra1106180","article-title":"Proteotoxicity and cardiac dysfunction\u2014Alzheimer\u2019s disease of the heart?","volume":"368","author":"Willis","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B279","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B280","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv"},{"key":"2026080909465417100_ehac244-B281","doi-asserted-by":"crossref","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","article-title":"Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis","volume":"4","author":"Waxman","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B282","first-page":"378","article-title":"Causes of late mortality with dual antiplatelet therapy after coronary stents","volume":"37","author":"Mauri","year":"2016","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B283","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2018.09.014","article-title":"Irreversible proteasome inhibition with carfilzomib as first line therapy in patients with newly diagnosed multiple myeloma: early in vivo cardiovascular effects","volume":"838","author":"Gavazzoni","year":"2018","journal-title":"Eur J Pharmacol"},{"key":"2026080909465417100_ehac244-B284","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"2026080909465417100_ehac244-B285","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/0002-9343(77)90870-1","article-title":"The conduction system in cardiac amyloidosis. Clinical and pathologic features of 23 patients","volume":"62","author":"Ridolfi","year":"1977","journal-title":"Am J Med"},{"key":"2026080909465417100_ehac244-B286","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B287","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","article-title":"Intracardiac thrombosis and embolism in patients with cardiac amyloidosis","volume":"116","author":"Feng","year":"2007","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B288","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1080\/10428194.2017.1393674","article-title":"Cardio-oncology in multiple myeloma: is it time for a specific focus?","volume":"59","author":"Mancuso","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026080909465417100_ehac244-B289","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/ejh.12677","article-title":"\u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma\u2014analysis of cardiac toxicity and predisposing factors","volume":"97","author":"Danhof","year":"2016","journal-title":"Eur J Haematol"},{"key":"2026080909465417100_ehac244-B290","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23:","author":"Garcia-Pavia","year":"2021;","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B291","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1161\/CIRCULATIONAHA.108.785014","article-title":"Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis","volume":"119","author":"Feng","year":"2009","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B292","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2014-05-576256","article-title":"Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction\/consolidation therapy for newly diagnosed multiple myeloma","volume":"125","author":"Sonneveld","year":"2015","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B293","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2013-07-511170","article-title":"Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma","volume":"122","author":"Wang","year":"2013","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B294","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/bjh.14970","article-title":"Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma","volume":"180","author":"Fradley","year":"2018","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B295","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B296","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"2026080909465417100_ehac244-B297","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.jacc.2019.01.035","article-title":"High prevalence of intracardiac thrombi in cardiac amyloidosis","volume":"73","author":"Martinez-Naharro","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B298","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"2026080909465417100_ehac244-B299","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2022","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B301","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B302","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma\u2014choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B303","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1080\/10428194.2017.1403020","article-title":"Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity","volume":"59","author":"Lendvai","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"2026080909465417100_ehac244-B304","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B305","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","article-title":"Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide","volume":"119","author":"Larocca","year":"2012","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B306","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2016.08.008","article-title":"Cost-effectiveness analysis of low-molecular-weight heparin versus aspirin thromboprophylaxis in patients newly diagnosed with multiple myeloma","volume":"145","author":"Chalayer","year":"2016","journal-title":"Thromb Res"},{"key":"2026080909465417100_ehac244-B307","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminhematol.2017.08.002","article-title":"Primary thromboembolic prevention in multiple myeloma patients: an exploratory meta-analysis on aspirin use","volume":"55","author":"Zoppellaro","year":"2018","journal-title":"Semin Hematol"},{"key":"2026080909465417100_ehac244-B308","doi-asserted-by":"crossref","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026080909465417100_ehac244-B309","first-page":"1","article-title":"Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Glen","year":"2022","journal-title":"Cardio Oncol"},{"key":"2026080909465417100_ehac244-B310","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B311","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B312","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B313","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2026080909465417100_ehac244-B314","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejca.2019.07.016","article-title":"Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management","volume":"119","author":"Gogas","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B315","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","author":"Banks","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"2026080909465417100_ehac244-B316","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080909465417100_ehac244-B317","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B318","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B319","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B320","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B321","doi-asserted-by":"crossref","first-page":"e000261","DOI":"10.1136\/jitc-2019-000261","article-title":"Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors","volume":"8","author":"Dolladille","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B322","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/ehaa884","article-title":"The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study","volume":"42","author":"D\u2019Souza","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B323","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B324","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B325","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaccao.2020.11.012","article-title":"The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity: JACC: CardioOncology primer","volume":"3","author":"Zhang","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B326","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B327","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijcard.2020.08.024","article-title":"Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy","volume":"322","author":"Schiffer","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B328","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s40425-019-0665-2","article-title":"Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies","volume":"7","author":"Naing","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B329","doi-asserted-by":"crossref","first-page":"102586","DOI":"10.1016\/j.autrev.2020.102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2026080909465417100_ehac244-B330","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor\u2013associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B331","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B332","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamacardio.2021.2241","article-title":"Clinical strategy for the diagnosis and treatment of immune checkpoint inhibitor-associated myocarditis: a narrative review","volume":"6","author":"Lehmann","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026080909465417100_ehac244-B333","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1200\/JCO.21.01806","article-title":"Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase 3 JAVELIN Renal 101 trial","volume":"40","author":"Rini","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B334","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B335","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/CIRCULATIONAHA.120.051753","article-title":"By releasing the brakes with immunotherapy, are we accelerating atherosclerosis?","volume":"142","author":"Kondapalli","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B336","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080909465417100_ehac244-B337","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","article-title":"Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"key":"2026080909465417100_ehac244-B338","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE Steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B339","doi-asserted-by":"crossref","first-page":"e000082","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genomic Precis Med"},{"key":"2026080909465417100_ehac244-B340","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1093\/cvr\/cvz020","article-title":"Cardiac arrhythmia considerations of hormone cancer therapies","volume":"115","author":"Barber","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026080909465417100_ehac244-B341","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B342","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eururo.2020.06.002","article-title":"Differential impact of gonadotropin-releasing hormone antagonist versus agonist on clinical safety and oncologic outcomes on patients with metastatic prostate cancer: a meta-analysis of randomized controlled trials","volume":"79","author":"Abufaraj","year":"2021","journal-title":"Eur Urol"},{"key":"2026080909465417100_ehac244-B343","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B344","doi-asserted-by":"crossref","first-page":"664741","DOI":"10.3389\/fonc.2021.664741","article-title":"Angiotensin system inhibitors may improve outcomes of patients with castration-resistant prostate cancer during abiraterone acetate treatment\u2014a cardio-oncology study","volume":"11","author":"Wilk","year":"2021","journal-title":"Front Oncol"},{"key":"2026080909465417100_ehac244-B345","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.118.034282","article-title":"Hypogonadism as a reversible cause of Torsades de Pointes in men","volume":"138","author":"Salem","year":"2018","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B346","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pharmthera.2016.07.005","article-title":"Influence of steroid hormones on ventricular repolarization","volume":"167","author":"Salem","year":"2016","journal-title":"Pharmacol Ther"},{"key":"2026080909465417100_ehac244-B347","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1161\/CIRCULATIONAHA.119.040162","article-title":"Androgenic effects on ventricular repolarization a translational study from the international pharmacovigilance database to iPSC-cardiomyocytes","volume":"140","author":"Salem","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B348","doi-asserted-by":"crossref","first-page":"e017267","DOI":"10.1161\/JAHA.120.017267","article-title":"Impact of medical castration on malignant arrhythmias in patients with prostate cancer","volume":"10","author":"Hasegawa","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B349","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.1161\/CIR.0000000000000986","article-title":"Recognition, prevention, and management of arrhythmias and autonomic disorders in cardio-oncology: a scientific statement from the American Heart Association","volume":"144","author":"Fradley","year":"2021","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B350","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s40261-017-0547-7","article-title":"Effect of degarelix, a gonadotropin-releasing hormone receptor antagonist for the treatment of prostate cancer, on cardiac repolarisation in a randomised, placebo and active comparator controlled thorough QT\/QTc trial in healthy men","volume":"37","author":"Olsson","year":"2017","journal-title":"Clin Drug Investig"},{"key":"2026080909465417100_ehac244-B351","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/S0140-6736(02)09088-8","article-title":"Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial","volume":"359","author":"Baum","year":"2002","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B352","volume-title":"Highlights of Prescribing Information","author":"ARIMIDEX\u00ae (anastrozole)","year":"2014"},{"key":"2026080909465417100_ehac244-B353","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Breast International Group (BIG) 1-98 Collaborative Group","year":"2005","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B354","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","article-title":"Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis","volume":"103","author":"Amir","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026080909465417100_ehac244-B355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jnci\/djx141","article-title":"Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis","volume":"110","author":"Goldvaser","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2026080909465417100_ehac244-B356","doi-asserted-by":"crossref","first-page":"e1034","DOI":"10.1634\/theoncologist.2018-0773","article-title":"Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer","volume":"24","author":"Curigliano","year":"2019","journal-title":"Oncologist"},{"key":"2026080909465417100_ehac244-B357","volume-title":"Highlights of Prescribing Information","author":"KISQALI (ribociclib)","year":"2018"},{"key":"2026080909465417100_ehac244-B358","volume-title":"Highlights of Prescribing Information","author":"IBRANCE (palbociclib)","year":"2018"},{"key":"2026080909465417100_ehac244-B359","volume-title":"Highlights of Prescribing Information","author":"VERZENIO (abemaciclib)","year":"2018"},{"key":"2026080909465417100_ehac244-B360","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s40259-019-00382-1","article-title":"Different cardiotoxicity of palbociclib and ribociclib in breast cancer: gene expression and pharmacological data analyses, biological basis, and therapeutic implications","volume":"33","author":"Santoni","year":"2019","journal-title":"BioDrugs"},{"key":"2026080909465417100_ehac244-B361","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B362","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B363","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B364","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2\u2013negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B365","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B366","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CAD.0000000000000589","article-title":"Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer","volume":"29","author":"Durairaj","year":"2018","journal-title":"Anticancer Drugs"},{"key":"2026080909465417100_ehac244-B367","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B368","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B369","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","article-title":"Cancer chemotherapy and cardiac arrhythmias: a review","volume":"38","author":"Tamargo","year":"2015","journal-title":"Drug Saf"},{"key":"2026080909465417100_ehac244-B370","first-page":"13","article-title":"Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (Review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"key":"2026080909465417100_ehac244-B371","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","article-title":"Clinical approach to cardiovascular toxicity of oral antineoplastic agents: JACC state-of-the-art review","volume":"77","author":"Rao","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B372","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B373","doi-asserted-by":"crossref","first-page":"viii500","DOI":"10.1093\/annonc\/mdy292.011","article-title":"Incidence of cardiac toxicities in patients with advanced non-small cell lung cancer treated with osimertinib: a combined analysis of two phase III randomized controlled trials","volume":"29","author":"Thein","year":"2018","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B374","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA Adverse Events Reporting System (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","article-title":"Cardiac adverse events in EGFR-mutated non-small cell lung cancer treated with osimertinib","volume":"2","author":"Kunimasa","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B376","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/JCO.20.01171","article-title":"Cardiac safety of osimertinib: a review of data","volume":"39","author":"Ewer","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B377","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080909465417100_ehac244-B378","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B379","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B380","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/CJI.0000000000000341","article-title":"Cardiovascular toxicity and mortality associated with adoptive cell therapy and tumor-infiltrating lymphocytes for advanced stage melanoma","volume":"44","author":"Fradley","year":"2021","journal-title":"J Immunother"},{"key":"2026080909465417100_ehac244-B381","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaccao.2020.02.011","article-title":"CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?","volume":"2","author":"Ghosh","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B382","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaccao.2020.04.012","article-title":"Cardiovascular effects of CAR T cell therapy: a restrospective study","volume":"2","author":"Lefebvre","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B383","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","article-title":"Cardiac events associated with chimeric antigen receptor T-cells (CAR-T): a VigiBase perspective","volume":"75","author":"Salem","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B384","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/CIRCULATIONAHA.120.048100","article-title":"Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma","volume":"142","author":"Ganatra","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B385","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.3390\/ijms22094590","article-title":"State-of-art of cellular therapy for acute leukemia","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026080909465417100_ehac244-B386","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B387","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41571-021-00474-4","article-title":"Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer","volume":"18","author":"Ragoonanan","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026080909465417100_ehac244-B388","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus M","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B389","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B390","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B391","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026080909465417100_ehac244-B392","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaccao.2021.06.007","article-title":"Past, present, and future of radiation-induced cardiotoxicity: refinements in targeting, surveillance, and risk stratification","volume":"3","author":"Bergom","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B393","doi-asserted-by":"crossref","first-page":"e021686","DOI":"10.1161\/JAHA.121.021686","article-title":"Radiation-induced cardiovascular disease: review of an underrecognized pathology","volume":"10","author":"Belzile-Dugas","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B394","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaccao.2021.07.008","article-title":"Coronary artery disease in young women after radiation therapy for breast cancer","volume":"3","author":"Carlson","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B395","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13014-019-1234-z","article-title":"Is mean heart dose a relevant surrogate parameter of left ventricle and coronary arteries exposure during breast cancer radiotherapy: a dosimetric evaluation based on individually-determined radiation dose (BACCARAT study)","volume":"14","author":"Jacob","year":"2019","journal-title":"Radiat Oncol"},{"key":"2026080909465417100_ehac244-B396","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.prro.2019.09.015","article-title":"The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era","volume":"10","author":"Hoppe","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"2026080909465417100_ehac244-B397","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo M","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026080909465417100_ehac244-B398","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2021.03.005","article-title":"Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy","author":"Atkins","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"2026080909465417100_ehac244-B399","doi-asserted-by":"crossref","first-page":"b4606","DOI":"10.1136\/bmj.b4606","article-title":"Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort","volume":"339","author":"Mulrooney","year":"2009","journal-title":"BMJ"},{"key":"2026080909465417100_ehac244-B400","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk","volume":"175","author":"Van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2026080909465417100_ehac244-B401","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ijrobp.2018.10.025","article-title":"Radiation dose-response for risk of myocardial infarction in breast cancer survivors","volume":"103","author":"Jacobse","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B402","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B403","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B404","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1470-2045(14)71221-5","article-title":"Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial","volume":"16","author":"Kunkler","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B405","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.adro.2020.03.009","article-title":"Concerns for active breathing control (ABC) with breast cancer in the era of COVID-19: maximizing infection control while minimizing heart dose","volume":"5","author":"Song","year":"2020","journal-title":"Adv Radiat Oncol"},{"key":"2026080909465417100_ehac244-B406","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","article-title":"Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold","volume":"54","author":"Petersen","year":"2015","journal-title":"Acta Oncol (Madr"},{"key":"2026080909465417100_ehac244-B407","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3109\/0284186X.2016.1142115","article-title":"Deep inspiration breath-hold volumetric modulated arc radiotherapy decreases dose to mediastinal structures in locally advanced lung cancer","volume":"55","author":"Persson","year":"2016","journal-title":"Acta Oncol (Madr"},{"key":"2026080909465417100_ehac244-B408","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B409","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11239-020-02344-9","article-title":"Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation","volume":"51","author":"Rotz","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2026080909465417100_ehac244-B410","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41409-020-01080-1","article-title":"Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation","volume":"56","author":"Oliveira","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026080909465417100_ehac244-B411","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B412","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1182\/blood-2006-10-054080","article-title":"Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation","volume":"110","author":"Tichelli","year":"2007","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B413","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/ejh.13482","article-title":"Clinical prevalence and outcome of cardiovascular events in the first 100 days postallogeneic hematopoietic stem cell transplant","volume":"106","author":"Alblooshi","year":"2021","journal-title":"Eur J Haematol"},{"key":"2026080909465417100_ehac244-B414","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jaccao.2021.02.011","article-title":"Early cardiac toxicity associated with post-transplant cyclophosphamide in allogeneic stem cell transplantation","volume":"3","author":"Dul\u00e9ry","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B415","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-021-00850-3","article-title":"Cardiovascular issues in hematopoietic stem cell transplantation (HSCT)","volume":"22","author":"L\u00f3pez-Fern\u00e1ndez","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"2026080909465417100_ehac244-B416","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1038\/s41409-021-01427-2","article-title":"Cardiac complications associated with hematopoietic stem-cell transplantation","volume":"56","author":"Ohmoto","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"2026080909465417100_ehac244-B417","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/10245330600774991","article-title":"Prognosis value of atrial natriuretic peptide and brain natriuretic peptide for heart failure in patients undergoing allogeneic bone marrow transplantation","volume":"11","author":"Takatsuka","year":"2006","journal-title":"Hematology"},{"key":"2026080909465417100_ehac244-B418","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bmt.1702507","article-title":"Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide","volume":"26","author":"Snowden","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"2026080909465417100_ehac244-B419","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaccao.2020.08.014","article-title":"Cardiac biomarkers during cancer therapy: practical applications for cardio-oncology","volume":"2","author":"Alvarez-Cardona","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B420","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/j.bbmt.2019.01.018","article-title":"Role of physical therapy before and after hematopoietic stem cell transplantation: white paper report","volume":"25","author":"Mohammed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080909465417100_ehac244-B421","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B422","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaccao.2020.07.007","article-title":"Cardiovascular toxicity with cisplatin in patients with testicular cancer: looking for something heavier than heavy metal","volume":"2","author":"Herrmann","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B423","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17474086.2021.1969911","article-title":"Safety of FLT3 inhibitors in patients with acute myeloid leukemia","volume":"14","author":"Cerchione","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"2026080909465417100_ehac244-B424","doi-asserted-by":"crossref","first-page":"7034","DOI":"10.21037\/tcr-20-1869","article-title":"Can ACEI\/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?\u2014A meta-analysis of randomized controlled trials","volume":"11","author":"Dong","year":"2020","journal-title":"Transl Cancer Res"},{"key":"2026080909465417100_ehac244-B425","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B426","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B427","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10549-019-05139-6","article-title":"Cardiac outcomes of trastuzumab therapy in patients with HER2-positive breast cancer and reduced left ventricular ejection fraction","volume":"175","author":"Hussain","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B428","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","article-title":"Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial","volume":"1","author":"Leong","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B429","first-page":"19","article-title":"The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Omland","year":"2022","journal-title":"Cardio Oncol"},{"key":"2026080909465417100_ehac244-B430","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1200\/JCO.2009.23.6950","article-title":"Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: A combined review of cardiac data from the National Surgical Adjuvant Breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials","volume":"28","author":"Russell","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B431","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","article-title":"Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment","volume":"23","author":"Ewer","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B432","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1200\/JCO.2005.04.9551","article-title":"Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience","volume":"24","author":"Guarneri","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B433","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-020-06053-y","article-title":"Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function","volume":"185","author":"Khoury","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B434","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B435","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCULATIONAHA.121.055816","article-title":"Electrocardiographic manifestations of immune checkpoint inhibitor myocarditis","volume":"144","author":"Power","year":"2021","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B436","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B437","doi-asserted-by":"crossref","first-page":"e003594","DOI":"10.1136\/jitc-2021-003594","article-title":"68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis","volume":"9","author":"Boughdad","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B438","doi-asserted-by":"crossref","first-page":"614997","DOI":"10.3389\/fcvm.2021.614997","article-title":"Early detection of checkpoint inhibitor-associated myocarditis using 68Ga-FAPI PET\/CT","volume":"8","author":"Finke","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026080909465417100_ehac244-B439","doi-asserted-by":"crossref","first-page":"8512","DOI":"10.21037\/apm-20-2620","article-title":"Myocarditis related to immune checkpoint inhibitors treatment: two case reports and literature review","volume":"10","author":"Chen","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2026080909465417100_ehac244-B440","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B441","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehz467","article-title":"2019 ESC Guidelines for the management of patients with supraventricular tachycardia","volume":"41","author":"Brugada","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B442","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B443","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B444","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B445","doi-asserted-by":"crossref","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026080909465417100_ehac244-B446","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jaccao.2020.12.001","article-title":"Management of immune checkpoint inhibitor\u2013induced myocarditis: the French Working Group\u2019s Plea for a pragmatic approach","volume":"3","author":"Thuny","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B447","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","article-title":"Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-\u03b1, in patients with moderate-to-severe heart failure: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B448","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B449","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B450","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Ther"},{"key":"2026080909465417100_ehac244-B451","doi-asserted-by":"crossref","first-page":"4534","DOI":"10.1158\/1078-0432.CCR-17-0540","article-title":"U.S. Food and Drug Administration approval summary: atezolizumab for metastatic non\u2013small cell lung cancer","volume":"23","author":"Weinstock","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026080909465417100_ehac244-B452","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jacc.2019.07.079","article-title":"Cardiovascular toxicities of immune checkpoint inhibitors: JACC review topic of the week","volume":"74","author":"Ball","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B453","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor\u2013associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B454","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B455","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2020.08.036","article-title":"Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-sectional FDA adverse events reporting system analysis: cardiovascular events with CAR-T therapy","volume":"26","author":"Guha","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026080909465417100_ehac244-B456","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2796.1990.tb00155.x","article-title":"Cardiac involvement in bone marrow transplantation: serial changes in left ventricular size, mass and performance","volume":"227","author":"Kupari","year":"1990","journal-title":"J Intern Med"},{"key":"2026080909465417100_ehac244-B457","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/bmt.2015.127","article-title":"Arrhythmias in the setting of hematopoietic cell transplants","volume":"50","author":"Tonorezos","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2026080909465417100_ehac244-B458","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B459","first-page":"1727","article-title":"A hospital and home-based exercise program to address functional decline in people following allogeneic stem cell transplantation","volume":"26","author":"Abo","year":"2018","journal-title":"Support Care Cancer"},{"key":"2026080909465417100_ehac244-B460","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-018-0681-2","article-title":"Exercise training and cardiovascular health in cancer patients","volume":"20","author":"Squires","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2026080909465417100_ehac244-B461","doi-asserted-by":"crossref","first-page":"e021333","DOI":"10.1136\/bmjopen-2017-021333","article-title":"Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study","volume":"8","author":"Keen","year":"2018","journal-title":"BMJ Open"},{"key":"2026080909465417100_ehac244-B462","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijcard.2020.02.036","article-title":"National prevalence, trends and outcomes of takotsubo syndrome in hospitalizations with prior history of mediastinal\/intrathoracic cancer and radiation therapy","volume":"309","author":"Desai","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B463","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ijcard.2017.02.093","article-title":"Prevalence of cancer in Takotsubo cardiomyopathy: short and long-term outcome","volume":"238","author":"Sattler","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B464","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ejhf.2368","article-title":"Pathophysiology of Takotsubo syndrome\u2014a joint scientific statement from the HFA TTS and Myocardial Function Working Group of the ESC\u2014Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications","volume":"24","author":"Omerovic","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B465","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ejhf.2400","article-title":"Pathophysiology of Takotsubo syndrome\u2014a joint scientific statement from the HFA TTS Study Group and Myocardial Function Working Group of the ESC\u2014Part 1: overview and the central role for catecholamines and sympathetic nervous system","volume":"24","author":"Omerovic","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B466","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cvr\/cvab210","article-title":"Circulating microRNAs predispose to Takotsubo syndrome following high-dose adrenaline exposure","volume":"118","author":"Couch","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026080909465417100_ehac244-B467","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International expert consensus document on Takotsubo syndrome (part II): diagnostic workup, outcome, and management","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B468","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International expert consensus document on Takotsubo syndrome (part I): clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B469","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/ejhf.424","article-title":"Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology","volume":"18","author":"Lyon","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B470","doi-asserted-by":"crossref","first-page":"13076","DOI":"10.1073\/pnas.1200419109","article-title":"Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis","volume":"109","author":"Demers","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026080909465417100_ehac244-B471","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s00392-020-01719-5","article-title":"Assessment of coronary artery disease during hospitalization for cancer treatment","volume":"110","author":"Mrotzek","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026080909465417100_ehac244-B472","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5114\/amsad.2017.72531","article-title":"A unique reason for coronary spasm causing temporary ST elevation myocardial infarction (inferior STEMI)\u2014systemic inflammatory response syndrome after use of pembrolizumab","volume":"2","author":"Nykl","year":"2017","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"2026080909465417100_ehac244-B473","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11523-018-0579-9","article-title":"Coronary toxicities of anti-PD-1 and anti-PD-L1 immunotherapies: a case report and review of the literature and international registries","volume":"13","author":"Ferreira","year":"2018","journal-title":"Target Oncol"},{"key":"2026080909465417100_ehac244-B474","first-page":"631","article-title":"Prevalence and outcome of patients with cancer and acute coronary syndrome undergoing percutaneous coronary intervention: a BleeMACS substudy","volume":"7","author":"Iannaccone","year":"2018","journal-title":"Eur Heart Journal Acute Cardiovasc Care"},{"key":"2026080909465417100_ehac244-B475","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/eurheartj\/ehz851","article-title":"Acute myocardial infarction treatments and outcomes in 6.5 million patients with a current or historical diagnosis of cancer in the USA","volume":"41","author":"Bharadwaj","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B476","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.amjcard.2013.08.019","article-title":"Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention","volume":"112","author":"Velders","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B477","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2019.11.001","article-title":"Ischemia and bleeding in cancer patients undergoing percutaneous coronary intervention","volume":"1","author":"Ueki","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B478","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/eurheartj\/ehy769","article-title":"Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States","volume":"40","author":"Potts","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B479","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00432-015-2056-5","article-title":"Analysis of outcomes of percutaneous coronary intervention in metastatic cancer patients with acute coronary syndrome over a 10-year period","volume":"142","author":"Guddati","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026080909465417100_ehac244-B480","doi-asserted-by":"crossref","first-page":"482","DOI":"10.21037\/atm.2017.11.29","article-title":"Temporal trends and outcomes of acute myocardial infarction in patients with cancer","volume":"5","author":"Pothineni","year":"2017","journal-title":"Ann Transl Med"},{"key":"2026080909465417100_ehac244-B481","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/clc.22007","article-title":"Treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Yusuf","year":"2012","journal-title":"Clin Cardiol"},{"key":"2026080909465417100_ehac244-B482","first-page":"947","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology\u2014Part 1: acute coronary syndromes and acute pericardial diseases","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080909465417100_ehac244-B483","first-page":"829","article-title":"Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis","volume":"10","author":"Mohamed","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026080909465417100_ehac244-B484","first-page":"E202","article-title":"SCAI Expert consensus statement: Evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiolog\u0131a Intervencionista)","volume":"87","author":"Iliescu","year":"2016","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B485","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ahj.2017.08.015","article-title":"\u2018Bringing on the light\u2019 in a complex clinical scenario: optical coherence tomography\u2013guided discontinuation of antiplatelet therapy in cancer patients with coronary artery disease (PROTECT-OCT registry)","volume":"194","author":"Iliescu","year":"2017","journal-title":"Am Heart J"},{"key":"2026080909465417100_ehac244-B486","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.amjcard.2018.07.033","article-title":"Safety of diagnostic and therapeutic cardiac catheterization in cancer patients with acute coronary syndrome and chronic thrombocytopenia","volume":"122","author":"Iliescu","year":"2018","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B487","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.bjc.6600967","article-title":"Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity","volume":"88","author":"Cianci","year":"2003","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B488","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.amjcard.2012.07.026","article-title":"Capecitabine-induced chest pain relieved by diltiazem","volume":"110","author":"Ambrosy","year":"2012","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B489","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s002800050877","article-title":"Failure of oral nitrate and calcium channel blocker therapy to prevent 5-fluorouracil-related myocardial ischemia: a case report","volume":"43","author":"Akpek","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026080909465417100_ehac244-B490","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B491","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000641","article-title":"Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association","volume":"139","author":"Campia","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B492","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B493","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"key":"2026080909465417100_ehac244-B494","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000505486","article-title":"Cardiovascular toxicity in cancer patients treated with tyrosine kinase inhibitors: a real-world single-center experience","volume":"98","author":"Novo","year":"2020","journal-title":"Oncology"},{"key":"2026080909465417100_ehac244-B495","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/14779072.2020.1718493","article-title":"Outcomes of percutaneous coronary interventions in cancer patients","volume":"18","author":"Bharadwaj","year":"2020","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026080909465417100_ehac244-B496","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/eurheartj\/ehaa1032","article-title":"Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA","volume":"42","author":"Kwok","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B497","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis. The Dutch Stent Thrombosis Registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B498","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B499","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11936-017-0550-6","article-title":"Valvular heart disease in cancer patients: etiology, diagnosis, and management","volume":"19","author":"Stewart","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026080909465417100_ehac244-B500","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"J Am Med Assoc"},{"key":"2026080909465417100_ehac244-B501","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting cardiovascular risk and subsequent heart failure among non-Hodgkin lymphoma survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B502","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B503","first-page":"37","article-title":"Valvular heart disease as a possible predictor of trastuzumab-induced cardiotoxicity in patients with breast cancer","volume":"10","author":"Sato","year":"2019","journal-title":"Mol Clin Oncol"},{"key":"2026080909465417100_ehac244-B504","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.amjcard.2016.05.052","article-title":"Comparison of results of transcatheter aortic valve implantation in patients with versus without active cancer","volume":"118","author":"Watanabe","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B505","first-page":"139","article-title":"Two cases of lobectomy for lung cancer after transcatheter aortic valve implantation","volume":"4","author":"Nagata","year":"2018","journal-title":"Surg Case Reports"},{"key":"2026080909465417100_ehac244-B506","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcin.2018.10.026","article-title":"Transcatheter aortic valve replacement in oncology patients with severe aortic stenosis","volume":"12","author":"Landes","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B507","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","article-title":"2021 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"43","author":"Vahanian","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B508","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.recesp.2019.03.017","article-title":"Atrial fibrillation in active cancer patients: expert position paper and recommendations","volume":"72","author":"L\u00f3pez-Fern\u00e1ndez","year":"2019","journal-title":"Rev Espa\u00f1ola Cardiol (English Ed)"},{"key":"2026080909465417100_ehac244-B509","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B510","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaccao.2021.03.006","article-title":"Risk of atrial fibrillation according to cancer type: a nationwide population-based study","volume":"3","author":"Yun","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B511","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/eurheartj\/ehab745","article-title":"Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis","volume":"43","author":"Guha","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B512","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijcard.2012.08.036","article-title":"Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients","volume":"165","author":"Hu","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B513","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B514","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejim.2018.10.012","article-title":"Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality","volume":"59","author":"Malavasi","year":"2019","journal-title":"Eur J Intern Med"},{"key":"2026080909465417100_ehac244-B515","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mayocp.2015.09.009","article-title":"Prevalence of preexisting cardiovascular disease in patients with different types of cancer the unmet need for onco-cardiology","volume":"91","author":"Al-Kindi","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2026080909465417100_ehac244-B516","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","article-title":"Anticancer drug-induced cardiac rhythm disorders: current knowledge and basic underlying mechanisms","volume":"189","author":"Alexandre","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2026080909465417100_ehac244-B517","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Oncol"},{"key":"2026080909465417100_ehac244-B518","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/bjh.17788","article-title":"Management of cardiovascular complications of Bruton tyrosine kinase inhibitors","volume":"196","author":"Tang","year":"2022","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B519","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/cncr.33470","article-title":"Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study","volume":"127","author":"Pastori","year":"2021","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B520","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1055\/s-0040-1716408","article-title":"The 4S-AF scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): a novel approach to in-depth characterization (rather than classification) of atrial fibrillation","volume":"121","author":"Potpara","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B521","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.33963\/KP.15638","article-title":"Cardioversion of recent-onset atrial fibrillation: current evidence, practical considerations, and controversies in a complex clinical scenario","volume":"78","author":"Boriani","year":"2020","journal-title":"Kardiol Pol"},{"key":"2026080909465417100_ehac244-B522","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jce.12619","article-title":"Pulmonary vein isolation for atrial fibrillation in the postpneumonectomy population: a feasibility, safety, and outcomes study","volume":"26","author":"Kanmanthareddy","year":"2015","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026080909465417100_ehac244-B523","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"2026080909465417100_ehac244-B524","first-page":"619","article-title":"Stroke prevention, evaluation of bleeding risk, and anticoagulant treatment management in atrial fibrillation contemporary international guidelines","volume":"35","author":"Proietti","year":"2019","journal-title":"Can J Cardiol"},{"key":"2026080909465417100_ehac244-B525","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/eurjpc\/zwaa054","article-title":"Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management","volume":"28","author":"Boriani","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B526","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/2047487318759858","article-title":"CHA2DS2-VASC score and risk of thromboembolism and bleeding in patients with atrial fibrillation and recent cancer","volume":"25","author":"D\u2019Souza","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B527","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/eurjpc\/zwaa087","article-title":"Anticoagulation for atrial fibrillation in active cancer: what the cardiologists think","volume":"28","author":"Farmakis","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B528","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1093\/ehjci\/jeab008","article-title":"EACVI recommendations on cardiovascular imaging for the detection of embolic sources: endorsed by the Canadian Society of Echocardiography","volume":"22","author":"Cohen","year":"2021","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B529","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026080909465417100_ehac244-B530","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"2026080909465417100_ehac244-B531","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ehjqcco\/qcy040","article-title":"Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: Observations from ROCKET AF","volume":"5","author":"Chen","year":"2019","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026080909465417100_ehac244-B532","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.amjmed.2017.06.026","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial","volume":"130","author":"Melloni","year":"2017","journal-title":"Am J Med"},{"key":"2026080909465417100_ehac244-B533","doi-asserted-by":"crossref","first-page":"e008987","DOI":"10.1161\/JAHA.118.008987","article-title":"Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the engage AF-TIMI 48 trial","volume":"7","author":"Fanola","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B534","first-page":"706","article-title":"Superior safety of direct oral anticoagulants compared to warfarin in patients with atrial fibrillation and underlying cancer: a national Veterans Affairs database study","volume":"16","author":"Sawant","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"2026080909465417100_ehac244-B535","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/bloodadvances.2017010694","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation","volume":"2","author":"Shah","year":"2018","journal-title":"Blood Adv"},{"key":"2026080909465417100_ehac244-B536","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11239-020-02304-3","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis","volume":"51","author":"Mariani","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"2026080909465417100_ehac244-B537","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaccao.2021.06.004","article-title":"Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients with active cancer","volume":"3","author":"Deitelzweig","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B538","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1002\/cam4.4241","article-title":"Mortality associated with the use of non-vitamin K antagonist oral anticoagulants in cancer patients: dabigatran versus rivaroxaban","volume":"10","author":"Lin","year":"2021","journal-title":"Cancer Med"},{"key":"2026080909465417100_ehac244-B539","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.amjcard.2020.12.003","article-title":"Procedural and short-term outcomes of percutaneous left atrial appendage closure in patients with cancer","volume":"141","author":"Isogai","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B540","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/europace\/euy110","article-title":"European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS)","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2026080909465417100_ehac244-B541","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.jacc.2018.07.088","article-title":"Risk of thromboembolism associated with atrial fibrillation following noncardiac surgery","volume":"72","author":"Butt","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B542","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jacep.2016.03.001","article-title":"Increased incidence of ventricular arrhythmias in patients with advanced cancer and implantable cardioverter-defibrillators","volume":"3","author":"Enriquez","year":"2017","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080909465417100_ehac244-B543","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J Physiol"},{"key":"2026080909465417100_ehac244-B544","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1016\/j.hrthm.2017.10.035","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"15","author":"Al-Khatib","year":"2018","journal-title":"Heart Rhythm"},{"key":"2026080909465417100_ehac244-B545","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.CIR.88.2.782","article-title":"Diagnostic criteria for the long QT syndrome. An update","volume":"88","author":"Schwartz","year":"1993","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B546","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1161\/CIR.0000000000000905","article-title":"Drug-induced arrhythmias: a scientific statement from the American Heart Association","volume":"142","author":"Tisdale","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B547","author":"AZCERT"},{"key":"2026080909465417100_ehac244-B548","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ctrv.2017.11.009","article-title":"Management of QT prolongation induced by anti-cancer drugs: target therapy and old agents. Different algorithms for different drugs","volume":"63","author":"Coppola","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"2026080909465417100_ehac244-B549","article-title":"ICH guideline E14\/S7B on clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential\u2014questions & answers","author":"European Medicines Agency","year":"2020","journal-title":"Sci Med Heal"},{"key":"2026080909465417100_ehac244-B550","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1007\/s00432-019-02927-x","article-title":"Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases","volume":"145","author":"Atallah-Yunes","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026080909465417100_ehac244-B551","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.lungcan.2021.08.014","article-title":"ALK inhibitor-induced bradycardia: a systematic review and meta-analysis","volume":"161","author":"Cirne","year":"2021","journal-title":"Lung Cancer"},{"key":"2026080909465417100_ehac244-B552","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.hfc.2019.06.010","article-title":"Hypertension in the cardio-oncology clinic","volume":"15","author":"Hassen","year":"2019","journal-title":"Heart Fail Clin"},{"key":"2026080909465417100_ehac244-B553","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma","volume":"8","author":"Szmit","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"2026080909465417100_ehac244-B554","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/annonc\/mdp025","article-title":"Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis","volume":"20","author":"Di Lorenzo","year":"2009","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B555","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clgc.2016.12.016","article-title":"Angiotensin inhibitors as treatment of sunitinib\/pazopanib-induced hypertension in metastatic renal cell carcinoma","volume":"15","author":"Penttil\u00e4","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"2026080909465417100_ehac244-B556","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B557","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026080909465417100_ehac244-B558","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2026080909465417100_ehac244-B559","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.thromres.2016.06.033","article-title":"Epidemiology of venous thromboembolism in the Framingham Heart Study","volume":"145","author":"Puurunen","year":"2016","journal-title":"Thromb Res"},{"key":"2026080909465417100_ehac244-B560","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer\u2014a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B561","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/cncr.25714","article-title":"Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B562","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0040-1708481","article-title":"A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer","volume":"120","author":"Abdulla","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B563","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1111\/jth.15001","article-title":"Risk scores for occult cancer in patients with unprovoked venous thromboembolism: results from an individual patient data meta-analysis","volume":"18","author":"Mulder","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026080909465417100_ehac244-B564","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B565","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1055\/a-1355-3549","article-title":"Comparison of different clinical prognostic scores in patients with pulmonary embolism and active cancer","volume":"121","author":"Li","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B566","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B567","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1093\/eurjpc\/zwab088","article-title":"Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function","volume":"29","author":"Mazzolai","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026080909465417100_ehac244-B568","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B569","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jjcc.2018.02.011","article-title":"Mechanism and management of cancer-associated thrombosis","volume":"72","author":"Mukai","year":"2018","journal-title":"J Cardiol"},{"key":"2026080909465417100_ehac244-B570","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2011.40.3584","article-title":"Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging","volume":"30","author":"Armstrong","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B571","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeaa244","article-title":"Left ventricular thrombus on cardiovascular magnetic resonance imaging in non-ischaemic cardiomyopathy","author":"Hooks","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B572","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B573","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"Hull","year":"2006","journal-title":"Am J Med"},{"key":"2026080909465417100_ehac244-B574","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"Deitcher","year":"2006","journal-title":"Clin Appl Thromb"},{"key":"2026080909465417100_ehac244-B575","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"Meyer","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026080909465417100_ehac244-B576","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA J Am Med Assoc"},{"key":"2026080909465417100_ehac244-B577","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ijcard.2015.10.166","article-title":"Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy","volume":"203","author":"Lee","year":"2016","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B578","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B579","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B580","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"2026080909465417100_ehac244-B581","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B582","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdz111","article-title":"Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants","volume":"30","author":"Ay","year":"2019","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B583","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B584","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a US claims data analysis","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B585","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"2026080909465417100_ehac244-B586","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jaccao.2020.06.001","article-title":"Direct oral anticoagulants in patients with active cancer: a systematic review and meta-analysis","volume":"2","author":"Sabatino","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B587","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2018-08-835595","article-title":"How I treat cancer-associated venous thromboembolism","volume":"133","author":"Kraaijpoel","year":"2019","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B588","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","article-title":"Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients","volume":"29","author":"Exter PL","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B589","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"2026080909465417100_ehac244-B590","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"2026080909465417100_ehac244-B591","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B592","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.3390\/cancers12051167","article-title":"Venous thromboembolism in cancer patients on simultaneous and palliative care","volume":"12","author":"Riondino","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026080909465417100_ehac244-B593","first-page":"2970","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients: a systematic review and network meta-analysis","volume":"9","author":"Xin","year":"2020","journal-title":"Ann Cardiothorac Surg"},{"key":"2026080909465417100_ehac244-B594","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B595","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa012385","article-title":"Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer","volume":"346","author":"Bergqvist","year":"2002","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B596","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B597","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS\u2013cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"2026080909465417100_ehac244-B598","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B599","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B600","first-page":"CD008500","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026080909465417100_ehac244-B601","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B602","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B603","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"2026080909465417100_ehac244-B604","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0049-3848(16)30106-2","article-title":"Predictors of recurrent venous thromboembolism and bleeding on anticoagulation","volume":"140","author":"Menapace","year":"2016","journal-title":"Thromb Res"},{"key":"2026080909465417100_ehac244-B605","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12872-020-01352-0","article-title":"Systematic review and meta-analysis of the prognostic impact of cancer among patients with acute coronary syndrome and\/or percutaneous coronary intervention","volume":"20","author":"Roule","year":"2020","journal-title":"BMC Cardiovasc Disord"},{"key":"2026080909465417100_ehac244-B606","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"2026080909465417100_ehac244-B607","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B608","first-page":"29","article-title":"SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019","volume":"94","author":"Baran","year":"2019","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B609","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1200\/JOP.2017.028902","article-title":"Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary","volume":"14","author":"Schiffer","year":"2018","journal-title":"J Oncol Pract"},{"key":"2026080909465417100_ehac244-B610","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1182\/bloodadvances.2019000369","article-title":"Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy","volume":"3","author":"Al-Samkari","year":"2019","journal-title":"Blood Adv"},{"key":"2026080909465417100_ehac244-B611","doi-asserted-by":"crossref","first-page":"e015598","DOI":"10.1161\/JAHA.119.015598","article-title":"Anticancer therapy-related increases in arterial stiffness: a systematic review and meta-analysis","volume":"9","author":"Parr","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026080909465417100_ehac244-B612","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12885-017-3313-6","article-title":"Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade","volume":"17","author":"Gambichler","year":"2017","journal-title":"BMC Cancer"},{"key":"2026080909465417100_ehac244-B613","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"2026080909465417100_ehac244-B614","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"key":"2026080909465417100_ehac244-B615","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B616","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B617","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ajpath.2014.10.021","article-title":"Chemotherapy-induced pulmonary hypertension: role of alkylating agents","volume":"185","author":"Ranchoux","year":"2015","journal-title":"Am J Pathol"},{"key":"2026080909465417100_ehac244-B618","doi-asserted-by":"crossref","first-page":"2002208","DOI":"10.1183\/13993003.02208-2020","article-title":"Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems","volume":"57","author":"Jevnikar","year":"2021","journal-title":"Eur Respir J"},{"key":"2026080909465417100_ehac244-B619","doi-asserted-by":"crossref","first-page":"180065","DOI":"10.1183\/16000617.0065-2018","article-title":"Tumoral pulmonary hypertension","volume":"28","author":"Price","year":"2019","journal-title":"Eur Respir Rev"},{"key":"2026080909465417100_ehac244-B620","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B621","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B622","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial diseases in patients with cancer: Contemporary prevalence, management and outcomes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B623","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.jacc.2020.08.003","article-title":"Effect of anti-inflammatory drugs on clinical outcomes in patients with malignant pericardial effusion","volume":"76","author":"Kim","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B624","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026080909465417100_ehac244-B625","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","article-title":"Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports","volume":"70","author":"Inno","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2026080909465417100_ehac244-B626","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2015.11.023","article-title":"Cause and long-term outcome of cardiac tamponade","volume":"117","author":"S\u00e1nchez-Enrique","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B627","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/cncy.21790","article-title":"Diagnostic yield of cytopathology in evaluating pericardial effusions: clinicopathologic analysis of 419 specimens","volume":"125","author":"Saab","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"2026080909465417100_ehac244-B628","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.amjcard.2013.05.066","article-title":"Retrospective comparison of outcomes, diagnostic value, and complications of percutaneous prolonged drainage versus surgical pericardiotomy of pericardial effusion associated with malignancy","volume":"112","author":"Patel","year":"2013","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B629","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","article-title":"Targeted cancer therapies with pericardial effusions requiring pericardiocentesis focusing on immune checkpoint inhibitors","volume":"123","author":"Palaskas","year":"2019","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B630","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"2026080909465417100_ehac244-B631","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/cncr.33292","article-title":"Cardiac biomarkers and association with subsequent cardiomyopathy and mortality among adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort","volume":"127","author":"Dixon","year":"2021","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B632","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2017.77.4414","article-title":"Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials","volume":"36","author":"Hershman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B633","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jcmg.2017.12.011","article-title":"Effect of traditional heart failure risk factors on myocardial dysfunction in adult survivors of childhood cancer","volume":"11","author":"Nolan","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B634","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10549-020-05703-5","article-title":"Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients","volume":"182","author":"Cho","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B635","doi-asserted-by":"crossref","first-page":"730","DOI":"10.33963\/KP.14889","article-title":"Cardiopulmonary exercise testing in adult cardiology: expert opinion of the Working Group of Cardiac Rehabilitation and Exercise Physiology of the Polish Cardiac Society","volume":"77","author":"Smarz","year":"2019","journal-title":"Kardiol Pol"},{"key":"2026080909465417100_ehac244-B636","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.2017.77.5809","article-title":"Efficacy of exercise therapy on cardiorespiratory fitness in patients with cancer: a systematic review and meta-analysis","volume":"36","author":"Scott","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B637","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jcsm.12042","article-title":"A framework for prescription in exercise-oncology research","volume":"6","author":"Sasso","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026080909465417100_ehac244-B638","first-page":"e13267","article-title":"High-intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: a meta-analysis","volume":"29","author":"Wallen","year":"2020","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2026080909465417100_ehac244-B639","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1001\/jamaoncol.2019.0038","article-title":"Effect of aerobic and resistance exercise intervention on cardiovascular disease risk in women with early-stage breast cancer: a randomized clinical trial","volume":"5","author":"Lee","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B640","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1038\/s41416-018-0044-7","article-title":"Effects of high-intensity interval training on fatigue and quality of life in testicular cancer survivors","volume":"118","author":"Adams","year":"2018","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B641","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11764-019-00747-z","article-title":"High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship","volume":"13","author":"Mijwel","year":"2019","journal-title":"J Cancer Surviv"},{"key":"2026080909465417100_ehac244-B642","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40798-021-00344-4","article-title":"High-intensity interval training in older adults: a scoping review","volume":"7","author":"Marriott","year":"2021","journal-title":"Sport Med - Open"},{"key":"2026080909465417100_ehac244-B643","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2015.04.059","article-title":"Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level","volume":"65","author":"Barac","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B644","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","article-title":"Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib","volume":"370","author":"Chu","year":"2007","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B645","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/cncr.23460","article-title":"Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor","volume":"112","author":"Khakoo","year":"2008","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B646","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaccao.2021.01.002","article-title":"How to diagnose and manage QT prolongation in cancer patients","volume":"3","author":"Kim","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B647","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(13)70548-5","article-title":"Childhood cancer survival in Europe 1999\u20132007: results of EUROCARE-5\u2014a population-based study","volume":"15","author":"Gatta","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B648","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1001\/jama.297.24.2705","article-title":"Medical assessment of adverse health outcomes in long-term survivors of childhood cancer","volume":"297","author":"Geenen","year":"2007","journal-title":"J Am Med Assoc"},{"key":"2026080909465417100_ehac244-B649","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1200\/JCO.2017.76.3920","article-title":"Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention","volume":"36","author":"Armenian","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B650","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1161\/CIRCULATIONAHA.116.024811","article-title":"Population-based long-term cardiac-specific mortality among 34 489 five-year survivors of childhood cancer in Great Britain","volume":"135","author":"Fidler","year":"2017","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B651","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/annonc\/mdf118","article-title":"Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review","volume":"13","author":"Kremer","year":"2002","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B652","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B653","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ejca.2021.06.021","article-title":"Coronary artery disease surveillance among childhood, adolescent and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"156","author":"van Dalen","year":"2021","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B654","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaccao.2020.11.013","article-title":"Refining the 10-year prediction of left ventricular systolic dysfunction in long-term survivors of childhood cancer","volume":"3","author":"Leerink","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B655","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B656","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B657","doi-asserted-by":"crossref","first-page":"e29473","DOI":"10.1002\/pbc.29473","article-title":"Early parental knowledge of late effect risks in children with cancer","volume":"69","author":"Carpenter","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2026080909465417100_ehac244-B658","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/eurheartj\/ehz781","article-title":"From trends to transformation: where cardio-oncology is to make a difference","volume":"40","author":"Herrmann","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B659","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B660","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-15639-5","article-title":"Fatal heart disease among cancer patients","volume":"11","author":"Stoltzfus","year":"2020","journal-title":"Nat Commun"},{"key":"2026080909465417100_ehac244-B661","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B662","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ejhf.1610","article-title":"Myocardial dysfunction in long-term breast cancer survivors treated at ages 40\u201350 years","volume":"22","author":"Jacobse","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B663","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1002\/cam4.1572","article-title":"Long-term risk of cardiovascular mortality in lymphoma survivors: a systematic review and meta-analysis","volume":"7","author":"Boyne","year":"2018","journal-title":"Cancer Med"},{"key":"2026080909465417100_ehac244-B664","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300 000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B665","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/jnci\/djaa194","article-title":"Long-term cause-specific mortality in Hodgkin lymphoma patients","volume":"113","author":"de Vries","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026080909465417100_ehac244-B666","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"key":"2026080909465417100_ehac244-B667","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)61094-6","article-title":"2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): An open-label, randomised controlled trial","volume":"382","author":"Goldhirsch","year":"2013","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B668","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1200\/JCO.2015.61.8413","article-title":"Long-term cardiac safety analysis of NCCTG N9831 (Alliance) adjuvant trastuzumab trial","volume":"34","author":"Advani","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B669","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B670","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.echo.2013.07.005","article-title":"Expert Consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography","volume":"26","author":"Lancellotti","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"2026080909465417100_ehac244-B671","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/ejhf.1758","article-title":"Long-term survivors of early breast cancer treated with chemotherapy are characterized by a pro-inflammatory biomarker profile compared to matched controls","volume":"22","author":"Tromp","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026080909465417100_ehac244-B672","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jaccao.2021.09.016","article-title":"The role of healthy lifestyle in cancer incidence and temporal transitions to cardiometabolic disease","volume":"3","author":"Cao","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B673","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/jcpt.12124","article-title":"Incidence and risk-factors of CHOP\/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"39","author":"Limat","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2026080909465417100_ehac244-B674","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B675","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions","volume":"327","author":"SOLVD Investigators","year":"1992","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B676","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B677","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2026080909465417100_ehac244-B678","doi-asserted-by":"crossref","first-page":"e008110","DOI":"10.1161\/CIRCHEARTFAILURE.120.008110","article-title":"Characteristics and outcomes of women developing heart failure after early stage breast cancer chemotherapy: a population-based matched cohort study","volume":"14","author":"Abdel-Qadir","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026080909465417100_ehac244-B679","doi-asserted-by":"crossref","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","article-title":"Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines","volume":"23","author":"Curigliano","year":"2012","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B680","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1040-8428(01)00227-X","article-title":"Radiation-associated cardiovascular disease","volume":"45","author":"Adams","year":"2003","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026080909465417100_ehac244-B681","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1200\/JCO.2016.72.0722","article-title":"Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials","volume":"35","author":"Taylor","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B682","doi-asserted-by":"crossref","first-page":"e003483","DOI":"10.1161\/CIRCINTERVENTIONS.115.003483","article-title":"Long-term mortality in patients with radiation-associated coronary artery disease treated with percutaneous coronary intervention","volume":"9","author":"Reed","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B683","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jcin.2014.05.035","article-title":"Outcomes after percutaneous coronary intervention with stents in patients treated with thoracic external beam radiation for cancer","volume":"7","author":"Liang","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B684","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/heartjnl-2017-312123","article-title":"How to prevent and manage radiation-induced coronary artery disease","volume":"104","author":"Cuomo","year":"2018","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B685","doi-asserted-by":"crossref","first-page":"537","DOI":"10.6004\/jnccn.2012.0051","article-title":"Late cardiovascular toxicity following chemotherapy for germ cell tumors","volume":"10","author":"Feldman","year":"2012","journal-title":"JNCCN J Natl Compr Cancer Netw"},{"key":"2026080909465417100_ehac244-B686","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/clc.22041","article-title":"Response to treatment and outcomes of acute coronary syndrome in the cancer population","volume":"35","author":"Sudhakar","year":"2012","journal-title":"Clin Cardiol"},{"key":"2026080909465417100_ehac244-B687","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJMc1214827","article-title":"Statin use and reduced cancer-related mortality","volume":"368","author":"Nielsen","year":"2013","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B688","first-page":"221","article-title":"Optimal management of coronary artery disease in cancer patients","volume":"5","author":"Han","year":"2019","journal-title":"Chronic Dis Transl Med"},{"key":"2026080909465417100_ehac244-B689","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.5603\/KP.2018.0228","article-title":"(2018 ESC\/EACTS Guidelines on myocardial revascularization)","volume":"76","author":"Neumann","year":"2018","journal-title":"Kardiol Pol"},{"key":"2026080909465417100_ehac244-B690","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/CIRCULATIONAHA.113.001435","article-title":"Long-term survival of patients with radiation heart disease undergoing cardiac surgery: a cohort study","volume":"127","author":"Wu","year":"2013","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B691","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1136\/heartjnl-2015-308765","article-title":"Radiation-induced valvular heart disease","volume":"102","author":"Gujral","year":"2016","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B692","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B693","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jaccao.2020.11.008","article-title":"Impact of cancer in patients undergoing transcatheter aortic valve replacement: a single-center study","volume":"2","author":"Lind","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B694","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jaccao.2021.07.005","article-title":"Transcatheter compared with surgical aortic valve replacement in patients with previous chest-directed radiation therapy","volume":"3","author":"Yazdchi","year":"2021","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B695","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.amjcard.2020.01.047","article-title":"Contemporary trends and outcomes of percutaneous and surgical mitral valve replacement or repair in patients with cancer","volume":"125","author":"Guha","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B696","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1016\/j.jcin.2020.08.010","article-title":"Transcatheter versus surgical aortic valve replacement in patients with prior mediastinal radiation","volume":"13","author":"Elbadawi","year":"2020","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B697","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40959-020-00062-y","article-title":"Outcomes after transcatheter aortic valve replacement in cancer survivors with prior chest radiation therapy: a systematic review and meta-analysis","volume":"6","author":"Zafar","year":"2020","journal-title":"Cardio-Oncology"},{"key":"2026080909465417100_ehac244-B698","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia"},{"key":"2026080909465417100_ehac244-B699","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/0959-8049(95)00460-2","article-title":"Secondary Raynaud\u2019s phenomenon and other late vascular complications following chemotherapy for testicular cancer","volume":"31A","author":"Berger","year":"1995","journal-title":"Eur J Cancer"},{"key":"2026080909465417100_ehac244-B700","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41416-020-01049-3","article-title":"Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy","volume":"123","author":"Stelwagen","year":"2020","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B701","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jcin.2014.12.233","article-title":"Subclinical carotid atherosclerosis and early vascular aging from long-term low-dose ionizing radiation exposure: a genetic, telomere, and vascular ultrasound study in cardiac catheterization laboratory staff","volume":"8","author":"Andreassi","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2026080909465417100_ehac244-B702","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0741-5214(99)70042-X","article-title":"Accelerated carotid artery disease after high-dose head and neck radiotherapy: is there a role for routine carotid duplex surveillance?","volume":"30","author":"Carmody","year":"1999","journal-title":"J Vasc Surg"},{"key":"2026080909465417100_ehac244-B703","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.oraloncology.2018.02.021","article-title":"The risk of carotid stenosis in head and neck cancer patients after radiation therapy","volume":"80","author":"Carpenter","year":"2018","journal-title":"Oral Oncol"},{"key":"2026080909465417100_ehac244-B704","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11886-019-1192-y","article-title":"Radiation-associated pericardial disease","volume":"21","author":"Szpakowski","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026080909465417100_ehac244-B705","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2006.08.071","article-title":"Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data?","volume":"67","author":"Schultz-Hector","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B706","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijrobp.2017.05.022","article-title":"Incidence and predictors of pericardial effusion after chemoradiation therapy for locally advanced non-small cell lung cancer","volume":"99","author":"Ning","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B707","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ijrobp.2007.10.056","article-title":"Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy","volume":"70","author":"Wei","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B708","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B709","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2019.11.021","article-title":"Management of acute and recurrent pericarditis: JACC state-of-the-art review","volume":"75","author":"Chiabrando","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B710","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3949\/ccjm.83a.15104","article-title":"Radiation-induced heart disease: a practical guide to diagnosis and management","volume":"83","author":"Donnellan","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"2026080909465417100_ehac244-B711","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.athoracsur.2004.04.008","article-title":"Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy","volume":"78","author":"Crestanello","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"2026080909465417100_ehac244-B712","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/hrt.2008.149088","article-title":"Radiation induced heart disease","volume":"95","author":"Heidenreich","year":"2009","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B713","first-page":"523","article-title":"Autonomic nervous system dysfunction in advanced cancer","volume":"10","author":"Walsh","year":"2002","journal-title":"Support Care Cancer"},{"key":"2026080909465417100_ehac244-B714","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40959-020-00065-9","article-title":"Quantitative assessment of cardiovascular autonomic impairment in cancer survivors: a single center case series","volume":"6","author":"Noor","year":"2020","journal-title":"Cardio-Oncology"},{"key":"2026080909465417100_ehac244-B715","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1158\/1055-9965.EPI-17-0510","article-title":"Blood pressure status in adult survivors of childhood cancer: a report from the St. Jude Lifetime Cohort Study","volume":"26","author":"Gibson","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026080909465417100_ehac244-B716","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000495698","article-title":"Diabetes and metabolic syndrome in survivors of childhood cancer","volume":"91","author":"Friedman","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"2026080909465417100_ehac244-B717","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3109\/0284186X.2010.529822","article-title":"Updated evidence in support of diet and exercise interventions in cancer survivors","volume":"50","author":"Pekmezi","year":"2011","journal-title":"Acta Oncol (Madr)"},{"key":"2026080909465417100_ehac244-B718","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2002.20.4.1128","article-title":"Weight loss in breast cancer patient management","volume":"20","author":"Chlebowski","year":"2002","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B719","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","article-title":"Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis","volume":"123","author":"Protani","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"2026080909465417100_ehac244-B720","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2009.26.8797","article-title":"Energetics in colorectal and prostate cancer","volume":"28","author":"Meyerhardt","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B721","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cncr.22443","article-title":"Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality","volume":"109","author":"Wright","year":"2007","journal-title":"Cancer"},{"key":"2026080909465417100_ehac244-B722","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1177\/107327481001700107","article-title":"The effects of obesity and obesity-related conditions on colorectal cancer prognosis","volume":"17","author":"Siegel","year":"2010","journal-title":"Cancer Control"},{"key":"2026080909465417100_ehac244-B723","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.2005.01.079","article-title":"Weight, weight gain, and survival after breast cancer diagnosis","volume":"23","author":"Kroenke","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B724","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1200\/JCO.2007.15.6687","article-title":"Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: Findings from Cancer and Leukemia Group B 89803","volume":"26","author":"Meyerhardt","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B725","doi-asserted-by":"crossref","first-page":"9295","DOI":"10.1200\/JCO.2005.02.0198","article-title":"Dietary patterns and survival after breast cancer diagnosis","volume":"23","author":"Kroenke","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B726","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2008.19.4035","article-title":"Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer","volume":"27","author":"Kwan","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B727","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/jama.298.7.754","article-title":"Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer","volume":"298","author":"Meyerhardt","year":"2007","journal-title":"J Am Med Assoc"},{"key":"2026080909465417100_ehac244-B728","doi-asserted-by":"crossref","first-page":"e19596","DOI":"10.1097\/MD.0000000000019596","article-title":"Impact of statin use on cancer-specific mortality and recurrence: a meta-analysis of 60 observational studies","volume":"99","author":"Yang","year":"2020","journal-title":"Medicine"},{"key":"2026080909465417100_ehac244-B729","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.numecd.2019.11.002","article-title":"Association between statin use and all-cause mortality in cancer survivors, based on the Korean health insurance service between 2002 and 2015","volume":"30","author":"Kim","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026080909465417100_ehac244-B730","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1093\/eurheartj\/ehab325","article-title":"Statin associated lower cancer risk and related mortality in patients with heart failure","volume":"42","author":"Ren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B731","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1200\/JCO.2009.23.2488","article-title":"Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial","volume":"28","author":"Galv\u00e3o","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B732","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11764-009-0110-5","article-title":"An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis","volume":"4","author":"Speck","year":"2010","journal-title":"J Cancer Surviv"},{"key":"2026080909465417100_ehac244-B733","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11936-016-0465-7","article-title":"Exercise and aerobic fitness to reduce cancer-related cardiovascular toxicity","volume":"18","author":"Campia","year":"2016","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"2026080909465417100_ehac244-B734","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B735","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2018.2254","article-title":"Association of exercise with mortality in adult survivors of childhood cancer","volume":"4","author":"Scott","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B736","first-page":"242","article-title":"Nutrition and physical activity guidelines for cancer survivors","volume":"62","author":"Rock","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"2026080909465417100_ehac244-B737","author":"CDC","year":"2013"},{"key":"2026080909465417100_ehac244-B738","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2016.11.040","article-title":"Cardiac outcomes with pregnancy after cardiotoxic therapy for childhood cancer","volume":"69","author":"Thompson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B739","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jaccao.2020.04.007","article-title":"Impact of cancer therapy-related cardiac dysfunction on risk of heart failure in pregnancy","volume":"2","author":"Nolan","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B740","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cancers11081046","article-title":"A retrospective evaluation of risk of peripartum cardiac dysfunction in survivors of childhood, adolescent and young adult malignancies","volume":"11","author":"Chait-Rubinek","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026080909465417100_ehac244-B741","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B742","doi-asserted-by":"crossref","first-page":"e884","DOI":"10.1161\/CIR.0000000000000772","article-title":"Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American Heart Association","volume":"141","author":"Mehta","year":"2020","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B743","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis","year":"2015","edition":"4th ed"},{"key":"2026080909465417100_ehac244-B744","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jtho.2015.11.009","article-title":"The 2015 WHO Classification of tumors of the heart and pericardium","volume":"11","author":"Burke","year":"2016","journal-title":"J Thorac Oncol"},{"key":"2026080909465417100_ehac244-B745","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2459\/JCM.0000000000000059","article-title":"Incidence rate of primary cardiac tumors: a 14-year population study","volume":"17","author":"Cresti","year":"2016","journal-title":"J Cardiovasc Med"},{"key":"2026080909465417100_ehac244-B746","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jacc.2018.05.026","article-title":"Neoplasia and the heart: pathological review of effects with clinical and radiological correlation","volume":"72","author":"Maleszewski","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B747","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jaccao.2020.05.009","article-title":"Cardiac tumors: JACC CardioOncology state-of-the-art review","volume":"2","author":"Tyebally","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B748","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jacc.2003.09.065","article-title":"Differential diagnosis of cardiac masses using contrast echocardiographic perfusion imaging","volume":"43","author":"Kirkpatrick","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B749","doi-asserted-by":"publisher","author":"Thiene","DOI":"10.1093\/med\/9780198784906.003.0386"},{"key":"2026080909465417100_ehac244-B750","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1540-8175.2011.01627.x","article-title":"Real time three-dimensional echocardiography evaluation of intracardiac masses","volume":"29","author":"Zaragosa-Macias","year":"2012","journal-title":"Echocardiography"},{"key":"2026080909465417100_ehac244-B751","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jacc.2011.05.027","article-title":"Characterization of cardiac tumors in children by cardiovascular magnetic resonance imaging: a multicenter experience","volume":"58","author":"Beroukhim","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B752","doi-asserted-by":"crossref","first-page":"856","DOI":"10.2967\/jnumed.111.095364","article-title":"Differentiation of malignant and benign cardiac tumors using 18F-FDG PET\/CT","volume":"53","author":"Rahbar","year":"2012","journal-title":"J Nucl Med"},{"key":"2026080909465417100_ehac244-B753","doi-asserted-by":"crossref","first-page":"9281","DOI":"10.1007\/s12410-014-9281-1","article-title":"Cardiac masses on cardiac CT: a review","volume":"7","author":"Kassop","year":"2014","journal-title":"Curr Cardiovasc Imaging Rep"},{"key":"2026080909465417100_ehac244-B754","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1016\/j.jcmg.2020.03.021","article-title":"Diagnostic accuracy of cardiac computed tomography and 18F-fluorodeoxyglucose with positron emission tomography in cardiac masses","volume":"13","author":"D\u2019Angelo","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B755","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(05)70093-0","article-title":"Cardiac tumours: diagnosis and management","volume":"6","author":"Butany","year":"2005","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B756","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000213049","article-title":"Sunitinib malate, a receptor tyrosine kinase inhibitor, is effective in the treatment of restrictive heart failure due to heart metastases from renal cell carcinoma","volume":"114","author":"Szmit","year":"2009","journal-title":"Cardiology"},{"key":"2026080909465417100_ehac244-B757","doi-asserted-by":"crossref","first-page":"vi160","DOI":"10.1093\/annonc\/mdt199","article-title":"Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Peccatori","year":"2013","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B758","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1007\/s12094-020-02491-8","article-title":"Multidisciplinary consensus on cancer management during pregnancy","volume":"23","author":"Cubillo","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026080909465417100_ehac244-B759","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/OP.20.00077","article-title":"Multidisciplinary management of cancer during pregnancy","volume":"16","author":"Silverstein","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2026080909465417100_ehac244-B760","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdz228","article-title":"Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting","volume":"30","author":"Amant","year":"2019","journal-title":"Ann Oncol"},{"key":"2026080909465417100_ehac244-B761","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1182\/blood.2019000961","article-title":"How I treat lymphoma in pregnancy","volume":"136","author":"Dunleavy","year":"2020","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B762","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1532-429X-16-1","article-title":"Cardiovascular magnetic resonance in pregnancy: insights from the Cardiac Hemodynamic Imaging and Remodeling in Pregnancy (CHIRP) study","volume":"16","author":"Ducas","year":"2014","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026080909465417100_ehac244-B763","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCIMAGING.111.970012","article-title":"Morphological and functional adaptation of the maternal heart during pregnancy","volume":"5","author":"Savu","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B764","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s11886-016-0761-6","article-title":"Echocardiography in pregnancy: part 2","volume":"18","author":"Narayanan","year":"2016","journal-title":"Curr Cardiol Rep"},{"key":"2026080909465417100_ehac244-B765","doi-asserted-by":"crossref","first-page":"e001293","DOI":"10.1136\/openhrt-2020-001293","article-title":"Pregnancy in a healthy population: dynamics of NTproBNP and hs-cTroponin T","volume":"7","author":"Furen\u00e4s","year":"2020","journal-title":"Open Heart"},{"key":"2026080909465417100_ehac244-B766","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jacc.2010.02.076","article-title":"B-type natriuretic peptide in pregnant women with heart disease","volume":"56","author":"Tanous","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B767","doi-asserted-by":"crossref","first-page":"697","DOI":"10.7326\/0003-4819-143-10-200511150-00006","article-title":"Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study","volume":"143","author":"Heit","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026080909465417100_ehac244-B768","doi-asserted-by":"crossref","first-page":"f6099","DOI":"10.1136\/bmj.f6099","article-title":"Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England","volume":"347","author":"Sultan","year":"2013","journal-title":"BMJ"},{"key":"2026080909465417100_ehac244-B769","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08956.x","article-title":"Risk of first venous thromboembolism in and around pregnancy: a population-based cohort study","volume":"156","author":"Sultan","year":"2012","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B770","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.6061\/clinics\/2018\/e368","article-title":"Risk assessment of venous thromboembolism and thromboprophylaxis in pregnant women hospitalized with cancer: preliminary results from a risk score","volume":"73","author":"Hase","year":"2018","journal-title":"Clinics (Sao Paulo)"},{"key":"2026080909465417100_ehac244-B771","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1136\/hrt.2004.040329","article-title":"Carcinoid heart disease: presentation, diagnosis, and management","volume":"90","author":"Fox","year":"2004","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B772","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B773","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2014.02.037","article-title":"The clinical presentation and management of carcinoid heart disease","volume":"173","author":"Dobson","year":"2014","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B774","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ehf2.12396","article-title":"Carcinoid heart disease involving the left heart: a case report and biomarker analysis","volume":"6","author":"Lichtenauer","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026080909465417100_ehac244-B775","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(17)30110-9","article-title":"Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study","volume":"18","author":"Halperin","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026080909465417100_ehac244-B776","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/CIRCULATIONAHA.107.701367","article-title":"Carcinoid heart disease","volume":"116","author":"Bhattacharyya","year":"2007","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B777","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1038\/sj.bjc.6601816","article-title":"Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease","volume":"90","author":"Zuetenhorst","year":"2004","journal-title":"Br J Cancer"},{"key":"2026080909465417100_ehac244-B778","doi-asserted-by":"crossref","first-page":"e73679","DOI":"10.1371\/journal.pone.0073679","article-title":"The association of a panel of biomarkers with the presence and severity of carcinoid heart disease: a cross-sectional study","volume":"8","author":"Dobson","year":"2013","journal-title":"PLoS One"},{"key":"2026080909465417100_ehac244-B779","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2008.18.7047","article-title":"Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor","volume":"27","author":"Korse","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B780","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.amjcard.2008.05.047","article-title":"Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease","volume":"102","author":"Bhattacharyya","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B781","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B782","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2143\/AC.65.2.2047065","article-title":"Carcinoid heart disease: case and literature review","volume":"65","author":"Dumoulein","year":"2010","journal-title":"Acta Cardiol"},{"key":"2026080909465417100_ehac244-B783","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jtcvs.2018.09.025","article-title":"Improving outcome of valve replacement for carcinoid heart disease","volume":"158","author":"Nguyen","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026080909465417100_ehac244-B784","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/icvts\/ivs212","article-title":"In patients with carcinoid syndrome undergoing valve replacement: will a biological valve have acceptable durability?","volume":"15","author":"Mabvuure","year":"2012","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026080909465417100_ehac244-B785","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jacc.2015.09.014","article-title":"Early and late outcomes of surgical treatment in carcinoid heart disease","volume":"66","author":"Connolly","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B786","doi-asserted-by":"crossref","first-page":"56","DOI":"10.14740\/cr986","article-title":"Incidence of atrioventricular block after valve replacement in carcinoid heart disease","volume":"11","author":"Sunjic","year":"2020","journal-title":"Cardiol Res"},{"key":"2026080909465417100_ehac244-B787","first-page":"356","article-title":"Results of contemporary valve surgery in patients with carcinoid heart disease","volume":"25","author":"Kuntze","year":"2016","journal-title":"J Heart Valve Dis"},{"key":"2026080909465417100_ehac244-B788","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jaccas.2019.11.089","article-title":"Percutaneous transcatheter valve-in-valve pulmonary and tricuspid replacement in carcinoid heart disease","volume":"2","author":"Luthra","year":"2020","journal-title":"JACC Case Reports"},{"key":"2026080909465417100_ehac244-B789","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccas.2020.03.001","article-title":"Avoiding a repeat sternotomy in recurrent carcinoid heart disease","volume":"2","author":"Zacks","year":"2020","journal-title":"JACC Case Reports"},{"key":"2026080909465417100_ehac244-B790","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCIMAGING.109.886846","article-title":"Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI","volume":"3","author":"Bhattacharyya","year":"2010","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B791","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease: clinical and echocardiographic spectrum in 74 patients","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B792","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B793","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jaccao.2019.08.002","article-title":"AL amyloidosis for the cardiologist and oncologist: epidemiology, diagnosis, and management","volume":"1","author":"Witteles","year":"2019","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B794","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B795","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B796","article-title":"NCCN Clinical Practice Guidelines in Oncology. Systemic Light Chain Amyloidosis Version 1","author":"National Comprehensive Cancer Network (NCCN)","year":"2021","journal-title":"Natl Compr Cancer Netw"},{"key":"2026080909465417100_ehac244-B797","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B798","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jaccao.2020.01.006","article-title":"Plasma hepatocyte growth factor for diagnosis and prognosis in light chain and transthyretin cardiac amyloidosis","volume":"2","author":"Zhang","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B799","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ajh.24756","article-title":"Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease","volume":"92","author":"Mohan","year":"2017","journal-title":"Am J Hematol"},{"key":"2026080909465417100_ehac244-B800","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"2026080909465417100_ehac244-B801","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","article-title":"Multimodality imaging in cardiac amyloidosis: a primer for cardiologists","volume":"21","author":"Jurcu\u0163","year":"2020","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B802","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaccao.2020.05.012","article-title":"Incremental value of global longitudinal strain for predicting survival in patients with advanced AL amyloidosis","volume":"2","author":"Lee Chuy","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026080909465417100_ehac244-B803","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ehf2.12511","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Brownrigg","year":"2019","journal-title":"ESC Heart Fail"},{"key":"2026080909465417100_ehac244-B804","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","article-title":"Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis","volume":"13","author":"Baggiano","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B805","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/leu.2012.100","article-title":"Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"2026080909465417100_ehac244-B806","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bjh.15717","article-title":"Grading cardiac response in AL amyloidosis: implications for relapse and survival","volume":"186","author":"Eckhert","year":"2019","journal-title":"Br J Haematol"},{"key":"2026080909465417100_ehac244-B807","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000495455","article-title":"Recent advances in the diagnosis, risk stratification, and management of systemic light-chain amyloidosis","volume":"141","author":"Vaxman","year":"2019","journal-title":"Acta Haematol"},{"key":"2026080909465417100_ehac244-B808","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacep.2020.01.004","article-title":"Management of arrhythmias in cardiac amyloidosis","volume":"6","author":"Giancaterino","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2026080909465417100_ehac244-B809","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jacc.2018.10.079","article-title":"Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis","volume":"73","author":"El-Am","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026080909465417100_ehac244-B810","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.1038\/s41598-019-44912-x","article-title":"Predictors of mortality in light chain cardiac amyloidosis with heart failure","volume":"9","author":"Tahir","year":"2019","journal-title":"Sci Rep"},{"key":"2026080909465417100_ehac244-B811","doi-asserted-by":"crossref","DOI":"10.1177\/1179546820963055","article-title":"Ventricular arrhythmias in cardiac amyloidosis: a review of current literature","volume":"14","author":"Khanna","year":"2020","journal-title":"Clin Med Insights Cardiol"},{"key":"2026080909465417100_ehac244-B812","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B813","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"2026080909465417100_ehac244-B814","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/13506129.2020.1835635","article-title":"The role of induction therapy before autologous stem cell transplantation in low disease burden AL amyloidosis patients","author":"Huang","year":"2021;28","journal-title":"Amyloid"},{"key":"2026080909465417100_ehac244-B815","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.jchf.2019.07.007","article-title":"A changing landscape of mortality for systemic light chain amyloidosis","volume":"7","author":"Barrett","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026080909465417100_ehac244-B816","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"key":"2026080909465417100_ehac244-B817","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B818","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"2026080909465417100_ehac244-B819","article-title":"Doxycycline combined with bortezomib\u2013cyclophosphamide\u2013dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial","author":"Shen","year":"2021","journal-title":"Circulation"},{"key":"2026080909465417100_ehac244-B820","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/ehjci\/jew298","article-title":"Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis","volume":"18","author":"Salinaro","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026080909465417100_ehac244-B821","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"2026080909465417100_ehac244-B822","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"2026080909465417100_ehac244-B823","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/pace.12572","article-title":"Risk of device malfunction in cancer patients with implantable cardiac device undergoing radiotherapy: a population-based cohort study","volume":"38","author":"Zaremba","year":"2015","journal-title":"Pacing Clin Electrophysiol"},{"key":"2026080909465417100_ehac244-B824","doi-asserted-by":"crossref","first-page":"e757","DOI":"10.1002\/mp.13838","article-title":"Management of radiotherapy patients with implanted cardiac pacemakers and defibrillators: a report of the AAPM TG-203","volume":"46","author":"Miften","year":"2019","journal-title":"Med Phys"},{"key":"2026080909465417100_ehac244-B825","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1748-717X-7-198","article-title":"Management of radiation oncology patients with a pacemaker or ICD: a new comprehensive practical guideline in The Netherlands","volume":"7","author":"Hurkmans","year":"2012","journal-title":"Radiat Oncol"},{"key":"2026080909465417100_ehac244-B826","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1016\/j.hrthm.2017.04.025","article-title":"2017 HRS expert consensus statement on magnetic resonance imaging and radiation exposure in patients with cardiovascular implantable electronic devices","volume":"14","author":"Indik","year":"2017","journal-title":"Heart Rhythm"},{"key":"2026080909465417100_ehac244-B827","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/europace\/euv135","article-title":"Radiotherapy in patients with pacemakers and implantable cardioverter defibrillators: a literature review","volume":"18","author":"Zaremba","year":"2016","journal-title":"Europace"},{"key":"2026080909465417100_ehac244-B828","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamaoncol.2015.1787","article-title":"Radiotherapy-induced malfunction in contemporary cardiovascular implantable electronic devices: clinical incidence and predictors","volume":"1","author":"Grant","year":"2015","journal-title":"JAMA Oncol"},{"key":"2026080909465417100_ehac244-B829","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ijcard.2017.12.061","article-title":"Management of patients with cardiac implantable electronic devices (CIED) undergoing radiotherapy: a consensus document from Associazione Italiana Aritmologia e Cardiostimolazione (AIAC), Associazione Italiana Radioterapia Oncologica (AIRO), Associazione Italiana Fisica Medica (AIFM)","volume":"255","author":"Zecchin","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026080909465417100_ehac244-B830","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ijrobp.2013.07.010","article-title":"Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors","volume":"87","author":"Gomez","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026080909465417100_ehac244-B831","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.amjcard.2020.04.045","article-title":"Radiotherapy in patients with a cardiac implantable electronic device","volume":"128","author":"Sharifzadehgan","year":"2020","journal-title":"Am J Cardiol"},{"key":"2026080909465417100_ehac244-B832","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.2196\/resprot.3407","article-title":"Development and evaluation of an educational E-tool to help patients with non-Hodgkin\u2019s lymphoma manage their personal care pathway","volume":"4","author":"Stienen","year":"2015","journal-title":"JMIR Res Protoc"},{"key":"2026080909465417100_ehac244-B833","first-page":"169","article-title":"A portable survivorship care plan: a tool that helps educate and improve knowledge in childhood cancer survivors","volume":"29","author":"Murphy","year":"2021","journal-title":"Support Care Cancer"},{"key":"2026080909465417100_ehac244-B834","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/eurheartj\/ehz935","article-title":"Cardiology care delivered to cancer patients","volume":"41","author":"Asteggiano","year":"2020","journal-title":"Eur Heart J"},{"key":"2026080909465417100_ehac244-B835","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjqcco\/qcaa069","article-title":"European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes","volume":"8","author":"Aktaa","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026080909465417100_ehac244-B836","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMsa1801495","article-title":"Quality of care in the United Kingdom after removal of financial incentives","volume":"379","author":"Minchin","year":"2018","journal-title":"N Engl J Med"},{"key":"2026080909465417100_ehac244-B837","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa1813621","article-title":"Health care spending, utilization, and quality 8 years into global payment","volume":"381","author":"Song","year":"2019","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4229\/51099586\/ehac244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/41\/4229\/51099586\/ehac244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:48:40Z","timestamp":1786283320000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/41\/4229\/6673995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,26]]},"references-count":837,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2022,8,26]]},"published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,8,26]]}}}